- published: 30 Sep 2015
- views: 844
Create your page here
-
remove the playlistValeant Pharmaceuticals
-
remove the playlistLatest Videos
-
remove the playlistLongest Videos
- remove the playlistValeant Pharmaceuticals
- remove the playlistLatest Videos
- remove the playlistLongest Videos
back to playlist
Canada based Valeant Pharmaceuticals price hikes of drugs long off patent has raised the ire of U.S.Congress. Cost of Isuprel or Isoprenaline increased 2,500 per cent. Nitropress went up 1,700 per cent in three years.
September 29, 2015
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals.
Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment.
- published: 05 Nov 2015
- views: 3500
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers.
- published: 02 Dec 2015
- views: 1355
Oct. 6 -- Activist investor Bill Ackman talks drug pricing and the controversy around Valeant Pharmaceuticals during an interview at the Bloomberg Markets Most Influential Summit.
--Subscribe to Bloomberg on YouTube: http://www.youtube.com/Bloomberg
- published: 07 Oct 2015
- views: 4915
Quebec-based Valeant Pharmaceutical's price hikes of drugs long off patent has raised the ire of U.S. legislators and frustrated Canadian physicians.
Click here for the full story: http://www.cbc.ca/1.3248265
»»» Subscribe to The National to watch more videos here: https://www.youtube.com/user/CBCTheNational?sub_confirmation=1
Voice Your Opinion & Connect With Us Online:
The National Updates on Facebook: https://www.facebook.com/thenational
The National Updates on Twitter: https://twitter.com/CBCTheNational
The National Updates on Google+: https://plus.google.com/+CBCTheNational
»»» »»» »»» »»» »»»
The National is CBC Television's flagship news program. Airing seven days a week, the show delivers news, feature documentaries and analysis from some of Canada's leading journalists.
- published: 30 Sep 2015
- views: 4351
Valeant Pharmaceuticals is the largest pharmaceutical company in Canada, over $100 Billion by market cap and has made over 30 acquisitions in the last 5 years. So should you own it? We take a look at the Bulls & Bears case for Valeant.
- published: 27 Jul 2015
- views: 778
Embattled pharmaceutical giant Valeant gave investors a bit of headache as the company cancelled an earnings call and withdrew guidance. WSJ 'Heard on the Street' columnist Charley Grant joins Tanya Rivero with analysis for investors. Photo: Bloomberg
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Follow WSJ on Facebook: http://www.facebook.com/wsjvideo
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJvideo
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
- published: 29 Feb 2016
- views: 73
–J. Michael Pearson, the CEO of Valeant Pharmaceuticals, admits that his business is all about profit
http://ringoffireradio.com/2015/10/09/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick/
–On the Bonus Show: Skin art preservation, another idiotic “good guy” with a gun, cigarette smoking in China, more…
Support TDPS by clicking (bookmark it too!) this link before shopping on Amazon: http://www.amazon.com/?tag=thedavpaksho-20
Website: https://www.davidpakman.com
Become a Member: https://www.davidpakman.com/membership
Be our Patron on Patreon: http://www.patreon.com/davidpakman
Discuss This on Reddit: http://www.reddit.com/r/thedavidpakmanshow/
Facebook: http://www.facebook.com/davidpakmanshow
TDPS Twitter: http://www.twitter.com/davidpakmanshow
David's Twitter: http://www.twitter.com/dpakman
TDPS Gear: http://www.davidpakman.com/gear
24/7 Voicemail Line: (219)-2DAVIDP
Subscribe to The David Pakman Show for more: http://www.youtube.com/subscription_center?add_user=midweekpolitics
Timely news is important! We upload new clips every day, 6-8 stories! Make sure to subscribe!
Broadcast on October 20, 2015
- published: 24 Oct 2015
- views: 4836
Oct. 21 -- Valeant Pharmaceuticals International Inc. called a short seller’s report that it used a strategy of recording fake sales to phony customers “erroneous” and defended its relationship with specialty pharmacies that distribute its drugs. Bloomberg's Drew Armstrong reports on "Bloomberg Markets."
- published: 21 Oct 2015
- views: 1642
U.S. stocks slipped on Tuesday after some disappointing consumer data. February retail sales fell 0.1 percent, matching economists’ forecasts. January's previously reported 0.2 percent increase was revised downward to a 0.4 percent decline. Meanwhile, the Bank of Japan kept its benchmark interest rates unchanged and in negative territory. No additional stimulus measures were announced, but more may be on the way soon. ‘I could see them engaging in some additional quantitative easing down the road,’ said Steve Friedman, senior investment strategist at BNP Paribas Investment Partners. ‘I think it makes sense to wait for the time being – I don’t think they are in any particular rush.’ Meanwhile, shares of Valeant Pharmaceuticals (VRX) slumped after the drugmaker posted weak guidance. It expects first quarter earnings between $1.30 and $1.55 a share, compared to a previously reported $2.35 to $2.55. TheStreet’s Scott Gamm reports from Wall Street.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
- published: 15 Mar 2016
- views: 10
Oct. 26 -- Andrew Left, founder at Citron Research, discusses calls by Valeant Pharmaceuticals Chief Executive Officer J. Michael Pearson for a Securities and Exchange Commission investigation into Citron Research and how hedge funds should have reacted to the price drop in Valeant shares. He speaks on "Bloomberg Markets."
- published: 26 Oct 2015
- views: 2912
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader.com/lp/Free-Guide-Trading-Tools/?utm_source=social&utm;_medium=youtube&utm;_campaign=resource%20guide
Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Valeant Pharmaceuticals International (VRX). Watch more VRX Technical Analysis Videos: https://claytrader.com/stock_chart/VRX/
The Stock Trading Reality Podcast - https://claytrader.com/podcast/
ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. Investing/trading in securities is highly speculative and carries an extremely high degree of risk.
- published: 15 Mar 2016
- views: 21
Valeant Pharmaceuticals International, Inc. (NYSE: VRX, TSX: VRX) is a pharmaceutical company with activities spanning the drug discovery pipeline from target identification through clinical trials and commercialization. The focus of the company is on neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of speciality chemical and radiochemical research, development and supply companies with a history stretching back to the 1960s. Kinerase(R), used kinetin as active entity is one of the most famous products of this company.
The company has undergone major management, operational and strategic restructurings since the 1990s when shareholders of several group units approved the merger of ICN Pharmaceuticals (founded by Milan Panić), ICN Biomedicals, SPI Pharmaceuticals and Viratek into a new global entity, ICN Pharmaceuticals, the immediate forebear of Valeant.
This page contains text from Wikipedia, the Free Encyclopedia -
http://en.wikipedia.org/wiki/Valeant_Pharmaceuticals
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
4:10Valeant Pharmaceuticals / Drug Price Profiteering
Valeant Pharmaceuticals / Drug Price ProfiteeringValeant Pharmaceuticals / Drug Price Profiteering
Canada based Valeant Pharmaceuticals price hikes of drugs long off patent has raised the ire of U.S.Congress. Cost of Isuprel or Isoprenaline increased 2,500 per cent. Nitropress went up 1,700 per cent in three years. September 29, 2015 -
5:03Bill Ackman defends Valeant
Bill Ackman defends ValeantBill Ackman defends Valeant
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals. Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment. -
3:57A Valeant Tug of War
A Valeant Tug of WarA Valeant Tug of War
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers. -
3:52Bill Ackman: There's a Lot of Misinformation on Drug Pricing
Bill Ackman: There's a Lot of Misinformation on Drug PricingBill Ackman: There's a Lot of Misinformation on Drug Pricing
Oct. 6 -- Activist investor Bill Ackman talks drug pricing and the controversy around Valeant Pharmaceuticals during an interview at the Bloomberg Markets Most Influential Summit. --Subscribe to Bloomberg on YouTube: http://www.youtube.com/Bloomberg -
2:31Valeant Pharmaceuticals in crosshairs of U.S. Congress
Valeant Pharmaceuticals in crosshairs of U.S. CongressValeant Pharmaceuticals in crosshairs of U.S. Congress
Quebec-based Valeant Pharmaceutical's price hikes of drugs long off patent has raised the ire of U.S. legislators and frustrated Canadian physicians. Click here for the full story: http://www.cbc.ca/1.3248265 »»» Subscribe to The National to watch more videos here: https://www.youtube.com/user/CBCTheNational?sub_confirmation=1 Voice Your Opinion & Connect With Us Online: The National Updates on Facebook: https://www.facebook.com/thenational The National Updates on Twitter: https://twitter.com/CBCTheNational The National Updates on Google+: https://plus.google.com/+CBCTheNational »»» »»» »»» »»» »»» The National is CBC Television's flagship news program. Airing seven days a week, the show delivers news, feature documentaries and analysis from some of Canada's leading journalists. -
7:22Bulls & Bears: Valeant Pharmaceuticals
Bulls & Bears: Valeant PharmaceuticalsBulls & Bears: Valeant Pharmaceuticals
Valeant Pharmaceuticals is the largest pharmaceutical company in Canada, over $100 Billion by market cap and has made over 30 acquisitions in the last 5 years. So should you own it? We take a look at the Bulls & Bears case for Valeant. -
3:47Heard: Valeant Gives Investors Headaches
Heard: Valeant Gives Investors HeadachesHeard: Valeant Gives Investors Headaches
Embattled pharmaceutical giant Valeant gave investors a bit of headache as the company cancelled an earnings call and withdrew guidance. WSJ 'Heard on the Street' columnist Charley Grant joins Tanya Rivero with analysis for investors. Photo: Bloomberg Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy More from the Wall Street Journal: Visit WSJ.com: http://www.wsj.com Follow WSJ on Facebook: http://www.facebook.com/wsjvideo Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJvideo Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/ -
3:14Pharma CEO Admits: Our Business is Profit, Not Helping Sick People
Pharma CEO Admits: Our Business is Profit, Not Helping Sick PeoplePharma CEO Admits: Our Business is Profit, Not Helping Sick People
–J. Michael Pearson, the CEO of Valeant Pharmaceuticals, admits that his business is all about profit http://ringoffireradio.com/2015/10/09/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick/ –On the Bonus Show: Skin art preservation, another idiotic “good guy” with a gun, cigarette smoking in China, more… Support TDPS by clicking (bookmark it too!) this link before shopping on Amazon: http://www.amazon.com/?tag=thedavpaksho-20 Website: https://www.davidpakman.com Become a Member: https://www.davidpakman.com/membership Be our Patron on Patreon: http://www.patreon.com/davidpakman Discuss This on Reddit: http://www.reddit.com/r/thedavidpakmanshow/ Facebook: http://www.facebook.com/davidpakmanshow TDPS Twitter: http://www.twitter.com/davidpakmanshow David's Twitter: http://www.twitter.com/dpakman TDPS Gear: http://www.davidpakman.com/gear 24/7 Voicemail Line: (219)-2DAVIDP Subscribe to The David Pakman Show for more: http://www.youtube.com/subscription_center?add_user=midweekpolitics Timely news is important! We upload new clips every day, 6-8 stories! Make sure to subscribe! Broadcast on October 20, 2015 -
3:25Valeant Calls Short Seller's Report 'Erroneous'
Valeant Calls Short Seller's Report 'Erroneous'Valeant Calls Short Seller's Report 'Erroneous'
Oct. 21 -- Valeant Pharmaceuticals International Inc. called a short seller’s report that it used a strategy of recording fake sales to phony customers “erroneous” and defended its relationship with specialty pharmacies that distribute its drugs. Bloomberg's Drew Armstrong reports on "Bloomberg Markets." -
1:17Valeant Pharmaceuticals Shares Tank on Weak Guidance
Valeant Pharmaceuticals Shares Tank on Weak GuidanceValeant Pharmaceuticals Shares Tank on Weak Guidance
U.S. stocks slipped on Tuesday after some disappointing consumer data. February retail sales fell 0.1 percent, matching economists’ forecasts. January's previously reported 0.2 percent increase was revised downward to a 0.4 percent decline. Meanwhile, the Bank of Japan kept its benchmark interest rates unchanged and in negative territory. No additional stimulus measures were announced, but more may be on the way soon. ‘I could see them engaging in some additional quantitative easing down the road,’ said Steve Friedman, senior investment strategist at BNP Paribas Investment Partners. ‘I think it makes sense to wait for the time being – I don’t think they are in any particular rush.’ Meanwhile, shares of Valeant Pharmaceuticals (VRX) slumped after the drugmaker posted weak guidance. It expects first quarter earnings between $1.30 and $1.55 a share, compared to a previously reported $2.35 to $2.55. TheStreet’s Scott Gamm reports from Wall Street. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet -
4:05Citron Research Founder: What Valeant's Doing 'Sounds Illegal'
Citron Research Founder: What Valeant's Doing 'Sounds Illegal'Citron Research Founder: What Valeant's Doing 'Sounds Illegal'
Oct. 26 -- Andrew Left, founder at Citron Research, discusses calls by Valeant Pharmaceuticals Chief Executive Officer J. Michael Pearson for a Securities and Exchange Commission investigation into Citron Research and how hedge funds should have reacted to the price drop in Valeant shares. He speaks on "Bloomberg Markets." -
4:10Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16 Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader.com/lp/Free-Guide-Trading-Tools/?utm_source=social&utm;_medium=youtube&utm;_campaign=resource%20guide Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Valeant Pharmaceuticals International (VRX). Watch more VRX Technical Analysis Videos: https://claytrader.com/stock_chart/VRX/ The Stock Trading Reality Podcast - https://claytrader.com/podcast/ ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. Investing/trading in securities is highly speculative and carries an extremely high degree of risk. -
3:43Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15 Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader.com/lp/Free-Guide-Trading-Tools/?utm_source=social&utm;_medium=youtube&utm;_campaign=resource%20guide Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Valeant Pharmaceuticals International (VRX). Watch more VRX Technical Analysis Videos: https://claytrader.com/stock_chart/VRX/ The Stock Trading Reality Podcast - https://claytrader.com/podcast/ ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. Investing/trading in securities is highly speculative and carries an extremely high degree of risk. VRX Stock Technical Analysis Stock Chart, VRX Stock Technical Analysis Stock Pick, VRX Stock Technical Analysis Penny Stock, VRX Stock Technical Analysis Penny Stock Pick, VRX Stock Technical Analysis Stock Alert, VRX Stock Technical Analysis How To Read Stock Charts, VRX Stock Technical Analysis Stock Chart Video, VRX Stock Technical Analysis Daily Chart, VRX Stock Technical Analysis Chart Review, VRX Stock Technical Analysis Stock Review -
24:01Valeant Pharma Autopsy: Counting the Lost Billions
Valeant Pharma Autopsy: Counting the Lost BillionsValeant Pharma Autopsy: Counting the Lost Billions
10 of the smartest investors in the world just lost sizable fortunes, in 2 months, on one stock. Valeant Pharma: http://www.zacks.com/stock/quote/VRX?cid=CS-YOUTUBE-FT-VID Mobileye: http://www.zacks.com/stock/quote/MBLY?cid=CS-YOUTUBE-FT-VID Microsoft: http://www.zacks.com/stock/quote/MSFT?cid=CS-YOUTUBE-FT-VID Allergan Plc: http://www.zacks.com/stock/quote/AGN?cid=CS-YOUTUBE-FT-VID Follow us on StockTwits: http://stocktwits.com/ZacksResearch Follow us on Twitter: https://twitter.com/ZacksResearch Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
- Acorda Therapeutics
- Adolor Corporation
- Agnico-Eagle Mines
- Agrium
- Alcon
- Alkermes (company)
- Allergan
- Alza
- Amgen
- ARC Resources
- ARYx Therapeutics
- Avax Technologies
- AVI BioPharma
- Bank of Montreal
- Barr Pharmaceuticals
- Barrick Gold
- Baxter International
- Bell Canada
- Biogen Idec
- Biolex
- Biovail
- Biovail Corporation
- Biovest
- Biovista
- Bombardier Inc.
- Bristol-Myers Squibb
- Cameco
- Canada
- Canadian Oil Sands
- Canadian Tire
- CancerVax
- Cenovus Energy
- CEO
- Cephalon
- Cesamet
- Chairman
- Clinical trial
- Combe Incorporated
- Commercialization
- CoTherix
- Covance
- Covidien
- Cutter Laboratories
- CytoSport
- CytRx
- Danco Laboratories
- Dermatology
- Diastat
- DNAPrint Genomics
- Drug discovery
- Efudex
- Eldorado Gold
- Elorac
- Enbridge
- Encana
- Endo Pharmaceuticals
- Enerplus
- Ethicon Endo-Surgery
- Ethicon Inc.
- Eugene Melnyk
- Forest Laboratories
- Fortis Inc.
- Genentech
- Genta (company)
- GenVec
- Gildan Activewear
- Gilead Sciences
- Goldcorp
- Hospira
- Husky Energy
- Iamgold
- ImClone Systems
- Imperial Oil
- Infectious disease
- Inmet Mining
- ISTA Pharmaceuticals
- Ivax Corporation
- J. Michael Pearson
- Johnson & Johnson
- Kinetic Concepts
- Kinetin
- King Pharmaceuticals
- Kinray
- Kinross Gold
- KV Pharmaceutical
- Laval, Quebec
- Loblaw Companies
- Magna International
- Manulife Financial
- McKesson Corporation
- McNeil Laboratories
- Melior Discovery
- Mentholatum
- Merck & Co.
- Mestinon
- Metro Inc.
- Milan Panić
- Miles Laboratories
- Mylan
- Myriad Genetics
- Nabilone
- Neurology
- Nexen
- Nuvelo
- Ortho Pharmaceutical
- OSI Pharmaceuticals
- Par Pharmaceutical
- Parke-Davis
- Penn West
- Perrigo
- Pfizer
- Prasco Laboratories
- Procter & Gamble
- Proteon Therapeutics
- Public company
- Purdue Pharma
- Qualitest
- Québec
- Regeneron
- Repros Therapeutics
- Research In Motion
- Ribavirin
- Royal Bank of Canada
- S&P; TSX 60
- Saputo Incorporated
- Savage Laboratories
- Schering-Plough
- Scotiabank
- Shaw Communications
- Shoppers Drug Mart
- Silver Wheaton
- SNC-Lavalin
- Sterling Drug
- Sun Life Financial
- Suncor Energy
- Talisman Energy
- Tanox
- Tec Laboratories
- Teck Resources
- Telus
- Template S&P; TSX 60
- Thomson Reuters
- Ticker symbol
- Tiens Biotech Group
- Tim Hortons
- TransAlta
- TransCanada Corp.
- Trevena Inc
- Trubion
- Upjohn
- Ventria Bioscience
- ViroPharma
- Wikipedia Bare URLs
- Wikipedia Link rot
- Wikipedia Stub
- WP REFLINKS
- Wyeth
- Yamana Gold
-
Valeant Pharmaceuticals / Drug Price Profiteering
Canada based Valeant Pharmaceuticals price hikes of drugs long off patent has raised the ire of U.S.Congress. Cost of Isuprel or Isoprenaline increased 2,500 per cent. Nitropress went up 1,700 per cent in three years. September 29, 2015 -
Bill Ackman defends Valeant
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals. Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment. -
A Valeant Tug of War
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers. -
Bill Ackman: There's a Lot of Misinformation on Drug Pricing
Oct. 6 -- Activist investor Bill Ackman talks drug pricing and the controversy around Valeant Pharmaceuticals during an interview at the Bloomberg Markets Most Influential Summit. --Subscribe to Bloomberg on YouTube: http://www.youtube.com/Bloomberg -
Valeant Pharmaceuticals in crosshairs of U.S. Congress
Quebec-based Valeant Pharmaceutical's price hikes of drugs long off patent has raised the ire of U.S. legislators and frustrated Canadian physicians. Click here for the full story: http://www.cbc.ca/1.3248265 »»» Subscribe to The National to watch more videos here: https://www.youtube.com/user/CBCTheNational?sub_confirmation=1 Voice Your Opinion & Connect With Us Online: The National Updates on Facebook: https://www.facebook.com/thenational The National Updates on Twitter: https://twitter.com/CBCTheNational The National Updates on Google+: https://plus.google.com/+CBCTheNational »»» »»» »»» »»» »»» The National is CBC Television's flagship news program. Airing seven days a week, the show delivers news, feature documentaries and analysis from some of Canada's leading journalists. -
Bulls & Bears: Valeant Pharmaceuticals
Valeant Pharmaceuticals is the largest pharmaceutical company in Canada, over $100 Billion by market cap and has made over 30 acquisitions in the last 5 years. So should you own it? We take a look at the Bulls & Bears case for Valeant. -
Heard: Valeant Gives Investors Headaches
Embattled pharmaceutical giant Valeant gave investors a bit of headache as the company cancelled an earnings call and withdrew guidance. WSJ 'Heard on the Street' columnist Charley Grant joins Tanya Rivero with analysis for investors. Photo: Bloomberg Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy More from the Wall Street Journal: Visit WSJ.com: http://www.wsj.com Follow WSJ on Facebook: http://www.facebook.com/wsjvideo Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJvideo Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/ -
Pharma CEO Admits: Our Business is Profit, Not Helping Sick People
–J. Michael Pearson, the CEO of Valeant Pharmaceuticals, admits that his business is all about profit http://ringoffireradio.com/2015/10/09/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick/ –On the Bonus Show: Skin art preservation, another idiotic “good guy” with a gun, cigarette smoking in China, more… Support TDPS by clicking (bookmark it too!) this link before shopping on Amazon: http://www.amazon.com/?tag=thedavpaksho-20 Website: https://www.davidpakman.com Become a Member: https://www.davidpakman.com/membership Be our Patron on Patreon: http://www.patreon.com/davidpakman Discuss This on Reddit: http://www.reddit.com/r/thedavidpakmanshow/ Facebook: http://www.facebook.com/davidpakmanshow TDPS Twitter: http://www.twitter.com/davidpakmanshow Da... -
Valeant Calls Short Seller's Report 'Erroneous'
Oct. 21 -- Valeant Pharmaceuticals International Inc. called a short seller’s report that it used a strategy of recording fake sales to phony customers “erroneous” and defended its relationship with specialty pharmacies that distribute its drugs. Bloomberg's Drew Armstrong reports on "Bloomberg Markets." -
Valeant Pharmaceuticals Shares Tank on Weak Guidance
U.S. stocks slipped on Tuesday after some disappointing consumer data. February retail sales fell 0.1 percent, matching economists’ forecasts. January's previously reported 0.2 percent increase was revised downward to a 0.4 percent decline. Meanwhile, the Bank of Japan kept its benchmark interest rates unchanged and in negative territory. No additional stimulus measures were announced, but more may be on the way soon. ‘I could see them engaging in some additional quantitative easing down the road,’ said Steve Friedman, senior investment strategist at BNP Paribas Investment Partners. ‘I think it makes sense to wait for the time being – I don’t think they are in any particular rush.’ Meanwhile, shares of Valeant Pharmaceuticals (VRX) slumped after the drugmaker posted weak guidance. It expec... -
Citron Research Founder: What Valeant's Doing 'Sounds Illegal'
Oct. 26 -- Andrew Left, founder at Citron Research, discusses calls by Valeant Pharmaceuticals Chief Executive Officer J. Michael Pearson for a Securities and Exchange Commission investigation into Citron Research and how hedge funds should have reacted to the price drop in Valeant shares. He speaks on "Bloomberg Markets." -
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16 Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader.com/lp/Free-Guide-Trading-Tools/?utm_source=social&utm;_medium=youtube&utm;_campaign=resource%20guide Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Valeant Pharmaceuticals International (VRX). Watch more VRX Technical Analysis Videos: https://claytrader.com/stock_chart/VRX/ The Stock Trading Reality Podcast - https://claytrader.com/podcast/ ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financia... -
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15 Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader.com/lp/Free-Guide-Trading-Tools/?utm_source=social&utm;_medium=youtube&utm;_campaign=resource%20guide Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Valeant Pharmaceuticals International (VRX). Watch more VRX Technical Analysis Videos: https://claytrader.com/stock_chart/VRX/ The Stock Trading Reality Podcast - https://claytrader.com/podcast/ ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financia... -
Valeant Pharma Autopsy: Counting the Lost Billions
10 of the smartest investors in the world just lost sizable fortunes, in 2 months, on one stock. Valeant Pharma: http://www.zacks.com/stock/quote/VRX?cid=CS-YOUTUBE-FT-VID Mobileye: http://www.zacks.com/stock/quote/MBLY?cid=CS-YOUTUBE-FT-VID Microsoft: http://www.zacks.com/stock/quote/MSFT?cid=CS-YOUTUBE-FT-VID Allergan Plc: http://www.zacks.com/stock/quote/AGN?cid=CS-YOUTUBE-FT-VID Follow us on StockTwits: http://stocktwits.com/ZacksResearch Follow us on Twitter: https://twitter.com/ZacksResearch Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch -
Valeant's Response to Fraud Claim Is 'Amateurish,' Citron Founder Says
Oct. 22 -- Andrew Left, founder at Citron Research, talks about Valeant Pharmaceuticals' response to his accusations about Philidor and Wall Street's reaction to the company. He speaks on "Bloomberg Markets." (Corrects show name.) -
Here’s What Valeant Pharmaceuticals Said on Its Emergency Conference Call to Investors
Valeant Pharmaceuticals (VRX), under fire amid accusations of accounting fraud, held an emergency conference call on Monday hoping to calm investors. Last week, short-selling research firm Citron said the company was the ‘pharmaceutical Enron.’ A report in the New York Times last week raised questions about the company’s use of specialty pharmacies. The scrutiny pushed the stock down about 40 percent and wiped out some $20 billion in market value over just five days. At issue is Valeant’s relationship with Philidor, a specialty pharmacy. Valeant paid $100 million last December for the option to purchase Philidor, but failed to disclose the transaction until its third quarter earnings call last week. The company says it didn’t have to reveal the relationship because Philidor was not conside... -
Controversial Valeant-linked pharmacy closing its doors
Southern Investigative Reporting Foundation’s Roddy Boyd and FBN’s Charlie Gasparino on the controversy over Valeant Pharmaceuticals’ relationship with Philidor. Watch Charlie Gasparino and Liz Claman talk about Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment. -
Valeant Pharmaceutical - Big Short as Stock is Halted and Hedge Funds Take Billions in Loses
Valeant Pharmaceutical stock is halted as hedge fund managers loss billions. Citron said in a report that it appears that Valeant and the specialty pharmacy Philidor have created the network, and that Philidor appears to own R&O; Pharmacy, a company Valeant has accused of improperly withholding payments. See links below on this report live and GET STARTED TODAY. Valeant Pharmaceuticals International Inc. defended its relationship with a specialty pharmacy that distributes some of its drugs, following a critical report that wiped as much as $20 billion from its market value on Wednesday. Hedge fund manager Bill Ackman buys 2 million additional shares in Valeant GET STARTED TODAY: http://www.stockmarketfunding.com/Open-an-Account After Hours Earnings: http://www.dailystockcharts.co... -
Valeant Pharmaceuticals Team 3
-
Valeant Pharmaceuticals price gouge: Is Congress to blame? | World Finance
A political football is being punted over Valeant’s price hikes, but it will not be until after the election before a resolution is found, says William E. Rhodes, Founder and Chief Investment Strategist at Rhodes Analytics For a full transcript visit: http://www.worldfinance.com/videos/valeant-pharmaceuticals-price-gouge-is-congress-to-blame For more World Finance videos go to http://www.worldfinance.com/videos/ -
Horizon Pharma CEO: Not A Mini-Valeant | Mad Money | CNBC
Its stock has been crushed lately thanks to Valeant comparisons. After its latest earnings, does the market have it all wrong? » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about Horizon Pharma here: http://cnb.cx/1klPXnI "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive... -
[470] The Valeant scandal and Steve Keen on China and Portugal
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow and will slow even further. Ameera David weighs in. Ameera also highlights a new smart Gmail feature that will be able to scan your email and offer quick replies. Then, Ameera and RT correspondent Manuel Rapalo update their earlier discussion on Airbnb’s fight in to stay legal in San Francisco and discuss Expedia’s $3.9 billion deal to buy Airbnb competitor HomeAway. Afterwards, Paul Craig Roberts gives us his take on the elimination of two popular social security claiming measures, part of his interview with Boom Bust’s Bianca Facchinei that will air Friday. After the break, Boom Bust’s Edward Harrison sits down with Steve Keen, h... -
Valeant Pharmaceuticals CEO Returns, But Company Postpones Release of Q4 Results
U.S. stocks opened slightly lower on Monday as Chinese officials intervened to prop up its slowing economy. China’s yuan was devalued to a three-week low and the world’s second largest economy also cut the amount of money banks are required to maintain on reserve. 'Real activity [in China] continues to slow - and indeed that's broadly the picture in global emerging markets,’ said Michael Ingram, a market strategist with BGC Partners, based in London. Meanwhile, Valeant Pharmaceuticals (VRX) CEO Michael Pearson is returning to the company. He was out for over two months with pneumonia. Valeant was also supposed to release its fourth quarter results on Monday, but has postponed them to an undisclosed date. Finally, Starbucks (SBUX) is coming to Italy. The global coffee giant opens its first ...
Valeant Pharmaceuticals / Drug Price Profiteering
- Order: Reorder
- Duration: 4:10
- Updated: 30 Sep 2015
- views: 844
Canada based Valeant Pharmaceuticals price hikes of drugs long off patent has raised the ire of U.S.Congress. Cost of Isuprel or Isoprenaline increased 2,500 pe...
Canada based Valeant Pharmaceuticals price hikes of drugs long off patent has raised the ire of U.S.Congress. Cost of Isuprel or Isoprenaline increased 2,500 per cent. Nitropress went up 1,700 per cent in three years.
September 29, 2015
wn.com/Valeant Pharmaceuticals Drug Price Profiteering
Canada based Valeant Pharmaceuticals price hikes of drugs long off patent has raised the ire of U.S.Congress. Cost of Isuprel or Isoprenaline increased 2,500 per cent. Nitropress went up 1,700 per cent in three years.
September 29, 2015
- published: 30 Sep 2015
- views: 844
Bill Ackman defends Valeant
- Order: Reorder
- Duration: 5:03
- Updated: 05 Nov 2015
- views: 3500
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals.
Watch Charlie Gasparino and Liz Claman talk a...
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals.
Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment.
wn.com/Bill Ackman Defends Valeant
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals.
Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment.
- published: 05 Nov 2015
- views: 3500
A Valeant Tug of War
- Order: Reorder
- Duration: 3:57
- Updated: 02 Dec 2015
- views: 1355
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysa...
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers.
wn.com/A Valeant Tug Of War
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers.
- published: 02 Dec 2015
- views: 1355
Bill Ackman: There's a Lot of Misinformation on Drug Pricing
- Order: Reorder
- Duration: 3:52
- Updated: 07 Oct 2015
- views: 4915
Oct. 6 -- Activist investor Bill Ackman talks drug pricing and the controversy around Valeant Pharmaceuticals during an interview at the Bloomberg Markets Most ...
Oct. 6 -- Activist investor Bill Ackman talks drug pricing and the controversy around Valeant Pharmaceuticals during an interview at the Bloomberg Markets Most Influential Summit.
--Subscribe to Bloomberg on YouTube: http://www.youtube.com/Bloomberg
wn.com/Bill Ackman There's A Lot Of Misinformation On Drug Pricing
Oct. 6 -- Activist investor Bill Ackman talks drug pricing and the controversy around Valeant Pharmaceuticals during an interview at the Bloomberg Markets Most Influential Summit.
--Subscribe to Bloomberg on YouTube: http://www.youtube.com/Bloomberg
- published: 07 Oct 2015
- views: 4915
Valeant Pharmaceuticals in crosshairs of U.S. Congress
- Order: Reorder
- Duration: 2:31
- Updated: 30 Sep 2015
- views: 4351
Quebec-based Valeant Pharmaceutical's price hikes of drugs long off patent has raised the ire of U.S. legislators and frustrated Canadian physicians.
Click here...
Quebec-based Valeant Pharmaceutical's price hikes of drugs long off patent has raised the ire of U.S. legislators and frustrated Canadian physicians.
Click here for the full story: http://www.cbc.ca/1.3248265
»»» Subscribe to The National to watch more videos here: https://www.youtube.com/user/CBCTheNational?sub_confirmation=1
Voice Your Opinion & Connect With Us Online:
The National Updates on Facebook: https://www.facebook.com/thenational
The National Updates on Twitter: https://twitter.com/CBCTheNational
The National Updates on Google+: https://plus.google.com/+CBCTheNational
»»» »»» »»» »»» »»»
The National is CBC Television's flagship news program. Airing seven days a week, the show delivers news, feature documentaries and analysis from some of Canada's leading journalists.
wn.com/Valeant Pharmaceuticals In Crosshairs Of U.S. Congress
Quebec-based Valeant Pharmaceutical's price hikes of drugs long off patent has raised the ire of U.S. legislators and frustrated Canadian physicians.
Click here for the full story: http://www.cbc.ca/1.3248265
»»» Subscribe to The National to watch more videos here: https://www.youtube.com/user/CBCTheNational?sub_confirmation=1
Voice Your Opinion & Connect With Us Online:
The National Updates on Facebook: https://www.facebook.com/thenational
The National Updates on Twitter: https://twitter.com/CBCTheNational
The National Updates on Google+: https://plus.google.com/+CBCTheNational
»»» »»» »»» »»» »»»
The National is CBC Television's flagship news program. Airing seven days a week, the show delivers news, feature documentaries and analysis from some of Canada's leading journalists.
- published: 30 Sep 2015
- views: 4351
Bulls & Bears: Valeant Pharmaceuticals
- Order: Reorder
- Duration: 7:22
- Updated: 27 Jul 2015
- views: 778
Valeant Pharmaceuticals is the largest pharmaceutical company in Canada, over $100 Billion by market cap and has made over 30 acquisitions in the last 5 years. ...
Valeant Pharmaceuticals is the largest pharmaceutical company in Canada, over $100 Billion by market cap and has made over 30 acquisitions in the last 5 years. So should you own it? We take a look at the Bulls & Bears case for Valeant.
wn.com/Bulls Bears Valeant Pharmaceuticals
Valeant Pharmaceuticals is the largest pharmaceutical company in Canada, over $100 Billion by market cap and has made over 30 acquisitions in the last 5 years. So should you own it? We take a look at the Bulls & Bears case for Valeant.
- published: 27 Jul 2015
- views: 778
Heard: Valeant Gives Investors Headaches
- Order: Reorder
- Duration: 3:47
- Updated: 29 Feb 2016
- views: 73
Embattled pharmaceutical giant Valeant gave investors a bit of headache as the company cancelled an earnings call and withdrew guidance. WSJ 'Heard on the Stree...
Embattled pharmaceutical giant Valeant gave investors a bit of headache as the company cancelled an earnings call and withdrew guidance. WSJ 'Heard on the Street' columnist Charley Grant joins Tanya Rivero with analysis for investors. Photo: Bloomberg
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Follow WSJ on Facebook: http://www.facebook.com/wsjvideo
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJvideo
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
wn.com/Heard Valeant Gives Investors Headaches
Embattled pharmaceutical giant Valeant gave investors a bit of headache as the company cancelled an earnings call and withdrew guidance. WSJ 'Heard on the Street' columnist Charley Grant joins Tanya Rivero with analysis for investors. Photo: Bloomberg
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Follow WSJ on Facebook: http://www.facebook.com/wsjvideo
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJvideo
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
- published: 29 Feb 2016
- views: 73
Pharma CEO Admits: Our Business is Profit, Not Helping Sick People
- Order: Reorder
- Duration: 3:14
- Updated: 24 Oct 2015
- views: 4836
–J. Michael Pearson, the CEO of Valeant Pharmaceuticals, admits that his business is all about profit
http://ringoffireradio.com/2015/10/09/valeant-pharmaceuti...
–J. Michael Pearson, the CEO of Valeant Pharmaceuticals, admits that his business is all about profit
http://ringoffireradio.com/2015/10/09/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick/
–On the Bonus Show: Skin art preservation, another idiotic “good guy” with a gun, cigarette smoking in China, more…
Support TDPS by clicking (bookmark it too!) this link before shopping on Amazon: http://www.amazon.com/?tag=thedavpaksho-20
Website: https://www.davidpakman.com
Become a Member: https://www.davidpakman.com/membership
Be our Patron on Patreon: http://www.patreon.com/davidpakman
Discuss This on Reddit: http://www.reddit.com/r/thedavidpakmanshow/
Facebook: http://www.facebook.com/davidpakmanshow
TDPS Twitter: http://www.twitter.com/davidpakmanshow
David's Twitter: http://www.twitter.com/dpakman
TDPS Gear: http://www.davidpakman.com/gear
24/7 Voicemail Line: (219)-2DAVIDP
Subscribe to The David Pakman Show for more: http://www.youtube.com/subscription_center?add_user=midweekpolitics
Timely news is important! We upload new clips every day, 6-8 stories! Make sure to subscribe!
Broadcast on October 20, 2015
wn.com/Pharma Ceo Admits Our Business Is Profit, Not Helping Sick People
–J. Michael Pearson, the CEO of Valeant Pharmaceuticals, admits that his business is all about profit
http://ringoffireradio.com/2015/10/09/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick/
–On the Bonus Show: Skin art preservation, another idiotic “good guy” with a gun, cigarette smoking in China, more…
Support TDPS by clicking (bookmark it too!) this link before shopping on Amazon: http://www.amazon.com/?tag=thedavpaksho-20
Website: https://www.davidpakman.com
Become a Member: https://www.davidpakman.com/membership
Be our Patron on Patreon: http://www.patreon.com/davidpakman
Discuss This on Reddit: http://www.reddit.com/r/thedavidpakmanshow/
Facebook: http://www.facebook.com/davidpakmanshow
TDPS Twitter: http://www.twitter.com/davidpakmanshow
David's Twitter: http://www.twitter.com/dpakman
TDPS Gear: http://www.davidpakman.com/gear
24/7 Voicemail Line: (219)-2DAVIDP
Subscribe to The David Pakman Show for more: http://www.youtube.com/subscription_center?add_user=midweekpolitics
Timely news is important! We upload new clips every day, 6-8 stories! Make sure to subscribe!
Broadcast on October 20, 2015
- published: 24 Oct 2015
- views: 4836
Valeant Calls Short Seller's Report 'Erroneous'
- Order: Reorder
- Duration: 3:25
- Updated: 21 Oct 2015
- views: 1642
Oct. 21 -- Valeant Pharmaceuticals International Inc. called a short seller’s report that it used a strategy of recording fake sales to phony customers “erroneo...
Oct. 21 -- Valeant Pharmaceuticals International Inc. called a short seller’s report that it used a strategy of recording fake sales to phony customers “erroneous” and defended its relationship with specialty pharmacies that distribute its drugs. Bloomberg's Drew Armstrong reports on "Bloomberg Markets."
wn.com/Valeant Calls Short Seller's Report 'Erroneous'
Oct. 21 -- Valeant Pharmaceuticals International Inc. called a short seller’s report that it used a strategy of recording fake sales to phony customers “erroneous” and defended its relationship with specialty pharmacies that distribute its drugs. Bloomberg's Drew Armstrong reports on "Bloomberg Markets."
- published: 21 Oct 2015
- views: 1642
Valeant Pharmaceuticals Shares Tank on Weak Guidance
- Order: Reorder
- Duration: 1:17
- Updated: 15 Mar 2016
- views: 10
U.S. stocks slipped on Tuesday after some disappointing consumer data. February retail sales fell 0.1 percent, matching economists’ forecasts. January's previou...
U.S. stocks slipped on Tuesday after some disappointing consumer data. February retail sales fell 0.1 percent, matching economists’ forecasts. January's previously reported 0.2 percent increase was revised downward to a 0.4 percent decline. Meanwhile, the Bank of Japan kept its benchmark interest rates unchanged and in negative territory. No additional stimulus measures were announced, but more may be on the way soon. ‘I could see them engaging in some additional quantitative easing down the road,’ said Steve Friedman, senior investment strategist at BNP Paribas Investment Partners. ‘I think it makes sense to wait for the time being – I don’t think they are in any particular rush.’ Meanwhile, shares of Valeant Pharmaceuticals (VRX) slumped after the drugmaker posted weak guidance. It expects first quarter earnings between $1.30 and $1.55 a share, compared to a previously reported $2.35 to $2.55. TheStreet’s Scott Gamm reports from Wall Street.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
wn.com/Valeant Pharmaceuticals Shares Tank On Weak Guidance
U.S. stocks slipped on Tuesday after some disappointing consumer data. February retail sales fell 0.1 percent, matching economists’ forecasts. January's previously reported 0.2 percent increase was revised downward to a 0.4 percent decline. Meanwhile, the Bank of Japan kept its benchmark interest rates unchanged and in negative territory. No additional stimulus measures were announced, but more may be on the way soon. ‘I could see them engaging in some additional quantitative easing down the road,’ said Steve Friedman, senior investment strategist at BNP Paribas Investment Partners. ‘I think it makes sense to wait for the time being – I don’t think they are in any particular rush.’ Meanwhile, shares of Valeant Pharmaceuticals (VRX) slumped after the drugmaker posted weak guidance. It expects first quarter earnings between $1.30 and $1.55 a share, compared to a previously reported $2.35 to $2.55. TheStreet’s Scott Gamm reports from Wall Street.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
- published: 15 Mar 2016
- views: 10
Citron Research Founder: What Valeant's Doing 'Sounds Illegal'
- Order: Reorder
- Duration: 4:05
- Updated: 26 Oct 2015
- views: 2912
Oct. 26 -- Andrew Left, founder at Citron Research, discusses calls by Valeant Pharmaceuticals Chief Executive Officer J. Michael Pearson for a Securities and E...
Oct. 26 -- Andrew Left, founder at Citron Research, discusses calls by Valeant Pharmaceuticals Chief Executive Officer J. Michael Pearson for a Securities and Exchange Commission investigation into Citron Research and how hedge funds should have reacted to the price drop in Valeant shares. He speaks on "Bloomberg Markets."
wn.com/Citron Research Founder What Valeant's Doing 'Sounds Illegal'
Oct. 26 -- Andrew Left, founder at Citron Research, discusses calls by Valeant Pharmaceuticals Chief Executive Officer J. Michael Pearson for a Securities and Exchange Commission investigation into Citron Research and how hedge funds should have reacted to the price drop in Valeant shares. He speaks on "Bloomberg Markets."
- published: 26 Oct 2015
- views: 2912
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
- Order: Reorder
- Duration: 4:10
- Updated: 15 Mar 2016
- views: 21
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytr...
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader.com/lp/Free-Guide-Trading-Tools/?utm_source=social&utm;_medium=youtube&utm;_campaign=resource%20guide
Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Valeant Pharmaceuticals International (VRX). Watch more VRX Technical Analysis Videos: https://claytrader.com/stock_chart/VRX/
The Stock Trading Reality Podcast - https://claytrader.com/podcast/
ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. Investing/trading in securities is highly speculative and carries an extremely high degree of risk.
wn.com/Valeant Pharmaceuticals International Vrx Stock Chart Technical Analysis For 03 15 16
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader.com/lp/Free-Guide-Trading-Tools/?utm_source=social&utm;_medium=youtube&utm;_campaign=resource%20guide
Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Valeant Pharmaceuticals International (VRX). Watch more VRX Technical Analysis Videos: https://claytrader.com/stock_chart/VRX/
The Stock Trading Reality Podcast - https://claytrader.com/podcast/
ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. Investing/trading in securities is highly speculative and carries an extremely high degree of risk.
- published: 15 Mar 2016
- views: 21
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
- Order: Reorder
- Duration: 3:43
- Updated: 04 Nov 2015
- views: 596
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytr...
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader.com/lp/Free-Guide-Trading-Tools/?utm_source=social&utm;_medium=youtube&utm;_campaign=resource%20guide
Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Valeant Pharmaceuticals International (VRX). Watch more VRX Technical Analysis Videos: https://claytrader.com/stock_chart/VRX/
The Stock Trading Reality Podcast - https://claytrader.com/podcast/
ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. Investing/trading in securities is highly speculative and carries an extremely high degree of risk.
VRX Stock Technical Analysis Stock Chart, VRX Stock Technical Analysis Stock Pick, VRX Stock Technical Analysis Penny Stock, VRX Stock Technical Analysis Penny Stock Pick, VRX Stock Technical Analysis Stock Alert, VRX Stock Technical Analysis How To Read Stock Charts, VRX Stock Technical Analysis Stock Chart Video, VRX Stock Technical Analysis Daily Chart, VRX Stock Technical Analysis Chart Review, VRX Stock Technical Analysis Stock Review
wn.com/Valeant Pharmaceuticals International Vrx Stock Chart Technical Analysis For 11 04 15
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader.com/lp/Free-Guide-Trading-Tools/?utm_source=social&utm;_medium=youtube&utm;_campaign=resource%20guide
Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Valeant Pharmaceuticals International (VRX). Watch more VRX Technical Analysis Videos: https://claytrader.com/stock_chart/VRX/
The Stock Trading Reality Podcast - https://claytrader.com/podcast/
ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. Investing/trading in securities is highly speculative and carries an extremely high degree of risk.
VRX Stock Technical Analysis Stock Chart, VRX Stock Technical Analysis Stock Pick, VRX Stock Technical Analysis Penny Stock, VRX Stock Technical Analysis Penny Stock Pick, VRX Stock Technical Analysis Stock Alert, VRX Stock Technical Analysis How To Read Stock Charts, VRX Stock Technical Analysis Stock Chart Video, VRX Stock Technical Analysis Daily Chart, VRX Stock Technical Analysis Chart Review, VRX Stock Technical Analysis Stock Review
- published: 04 Nov 2015
- views: 596
Valeant Pharma Autopsy: Counting the Lost Billions
- Order: Reorder
- Duration: 24:01
- Updated: 19 Nov 2015
- views: 884
10 of the smartest investors in the world just lost sizable fortunes, in 2 months, on one stock.
Valeant Pharma: http://www.zacks.com/stock/quote/VRX?cid=CS-YO...
10 of the smartest investors in the world just lost sizable fortunes, in 2 months, on one stock.
Valeant Pharma: http://www.zacks.com/stock/quote/VRX?cid=CS-YOUTUBE-FT-VID
Mobileye: http://www.zacks.com/stock/quote/MBLY?cid=CS-YOUTUBE-FT-VID
Microsoft: http://www.zacks.com/stock/quote/MSFT?cid=CS-YOUTUBE-FT-VID
Allergan Plc: http://www.zacks.com/stock/quote/AGN?cid=CS-YOUTUBE-FT-VID
Follow us on StockTwits: http://stocktwits.com/ZacksResearch
Follow us on Twitter: https://twitter.com/ZacksResearch
Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
wn.com/Valeant Pharma Autopsy Counting The Lost Billions
10 of the smartest investors in the world just lost sizable fortunes, in 2 months, on one stock.
Valeant Pharma: http://www.zacks.com/stock/quote/VRX?cid=CS-YOUTUBE-FT-VID
Mobileye: http://www.zacks.com/stock/quote/MBLY?cid=CS-YOUTUBE-FT-VID
Microsoft: http://www.zacks.com/stock/quote/MSFT?cid=CS-YOUTUBE-FT-VID
Allergan Plc: http://www.zacks.com/stock/quote/AGN?cid=CS-YOUTUBE-FT-VID
Follow us on StockTwits: http://stocktwits.com/ZacksResearch
Follow us on Twitter: https://twitter.com/ZacksResearch
Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
- published: 19 Nov 2015
- views: 884
Valeant's Response to Fraud Claim Is 'Amateurish,' Citron Founder Says
- Order: Reorder
- Duration: 1:59
- Updated: 22 Oct 2015
- views: 2698
Oct. 22 -- Andrew Left, founder at Citron Research, talks about Valeant Pharmaceuticals' response to his accusations about Philidor and Wall Street's reaction t...
Oct. 22 -- Andrew Left, founder at Citron Research, talks about Valeant Pharmaceuticals' response to his accusations about Philidor and Wall Street's reaction to the company. He speaks on "Bloomberg Markets." (Corrects show name.)
wn.com/Valeant's Response To Fraud Claim Is 'Amateurish,' Citron Founder Says
Oct. 22 -- Andrew Left, founder at Citron Research, talks about Valeant Pharmaceuticals' response to his accusations about Philidor and Wall Street's reaction to the company. He speaks on "Bloomberg Markets." (Corrects show name.)
- published: 22 Oct 2015
- views: 2698
Here’s What Valeant Pharmaceuticals Said on Its Emergency Conference Call to Investors
- Order: Reorder
- Duration: 1:14
- Updated: 26 Oct 2015
- views: 143
Valeant Pharmaceuticals (VRX), under fire amid accusations of accounting fraud, held an emergency conference call on Monday hoping to calm investors. Last week,...
Valeant Pharmaceuticals (VRX), under fire amid accusations of accounting fraud, held an emergency conference call on Monday hoping to calm investors. Last week, short-selling research firm Citron said the company was the ‘pharmaceutical Enron.’ A report in the New York Times last week raised questions about the company’s use of specialty pharmacies. The scrutiny pushed the stock down about 40 percent and wiped out some $20 billion in market value over just five days. At issue is Valeant’s relationship with Philidor, a specialty pharmacy. Valeant paid $100 million last December for the option to purchase Philidor, but failed to disclose the transaction until its third quarter earnings call last week. The company says it didn’t have to reveal the relationship because Philidor was not considered material to Valeant’s business, and thus was exempt from reporting rules. The company says Philidor accounts for 5.9 percent of Valeant’s net revenue since the start of the year. Aside from Philidor, Valeant said it consolidates two other specialty pharmacies, including one in Indonesia and another in the United Arab Emirates.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
wn.com/Here’S What Valeant Pharmaceuticals Said On Its Emergency Conference Call To Investors
Valeant Pharmaceuticals (VRX), under fire amid accusations of accounting fraud, held an emergency conference call on Monday hoping to calm investors. Last week, short-selling research firm Citron said the company was the ‘pharmaceutical Enron.’ A report in the New York Times last week raised questions about the company’s use of specialty pharmacies. The scrutiny pushed the stock down about 40 percent and wiped out some $20 billion in market value over just five days. At issue is Valeant’s relationship with Philidor, a specialty pharmacy. Valeant paid $100 million last December for the option to purchase Philidor, but failed to disclose the transaction until its third quarter earnings call last week. The company says it didn’t have to reveal the relationship because Philidor was not considered material to Valeant’s business, and thus was exempt from reporting rules. The company says Philidor accounts for 5.9 percent of Valeant’s net revenue since the start of the year. Aside from Philidor, Valeant said it consolidates two other specialty pharmacies, including one in Indonesia and another in the United Arab Emirates.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
- published: 26 Oct 2015
- views: 143
Controversial Valeant-linked pharmacy closing its doors
- Order: Reorder
- Duration: 6:49
- Updated: 03 Nov 2015
- views: 227
Southern Investigative Reporting Foundation’s Roddy Boyd and FBN’s Charlie Gasparino on the controversy over Valeant Pharmaceuticals’ relationship with Philidor...
Southern Investigative Reporting Foundation’s Roddy Boyd and FBN’s Charlie Gasparino on the controversy over Valeant Pharmaceuticals’ relationship with Philidor.
Watch Charlie Gasparino and Liz Claman talk about Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment.
wn.com/Controversial Valeant Linked Pharmacy Closing Its Doors
Southern Investigative Reporting Foundation’s Roddy Boyd and FBN’s Charlie Gasparino on the controversy over Valeant Pharmaceuticals’ relationship with Philidor.
Watch Charlie Gasparino and Liz Claman talk about Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment.
- published: 03 Nov 2015
- views: 227
Valeant Pharmaceutical - Big Short as Stock is Halted and Hedge Funds Take Billions in Loses
- Order: Reorder
- Duration: 7:00
- Updated: 21 Oct 2015
- views: 666
Valeant Pharmaceutical stock is halted as hedge fund managers loss billions. Citron said in a report that it appears that Valeant and the specialty pharmacy Ph...
Valeant Pharmaceutical stock is halted as hedge fund managers loss billions. Citron said in a report that it appears that Valeant and the specialty pharmacy Philidor have created the network, and that Philidor appears to own R&O; Pharmacy, a company Valeant has accused of improperly withholding payments.
See links below on this report live and GET STARTED TODAY.
Valeant Pharmaceuticals International Inc. defended its relationship with a specialty pharmacy that distributes some of its drugs, following a critical report that wiped as much as $20 billion from its market value on Wednesday.
Hedge fund manager Bill Ackman buys 2 million additional shares in Valeant
GET STARTED TODAY:
http://www.stockmarketfunding.com/Open-an-Account
After Hours Earnings:
http://www.dailystockcharts.com/after-hour-earnings/
VRX:
http://www.stockmarketfunding.com/Videos/Stocks/VRX
Main Web Sites:
http://www.dailystockcharts.com/ AND http://www.stockmarketfunding.com/
MY GOOGLE +:
https://plus.google.com/u/0/107014460504455758500/about
Contact US:
http://www.dailystockcharts.com/contact-us/
wn.com/Valeant Pharmaceutical Big Short As Stock Is Halted And Hedge Funds Take Billions In Loses
Valeant Pharmaceutical stock is halted as hedge fund managers loss billions. Citron said in a report that it appears that Valeant and the specialty pharmacy Philidor have created the network, and that Philidor appears to own R&O; Pharmacy, a company Valeant has accused of improperly withholding payments.
See links below on this report live and GET STARTED TODAY.
Valeant Pharmaceuticals International Inc. defended its relationship with a specialty pharmacy that distributes some of its drugs, following a critical report that wiped as much as $20 billion from its market value on Wednesday.
Hedge fund manager Bill Ackman buys 2 million additional shares in Valeant
GET STARTED TODAY:
http://www.stockmarketfunding.com/Open-an-Account
After Hours Earnings:
http://www.dailystockcharts.com/after-hour-earnings/
VRX:
http://www.stockmarketfunding.com/Videos/Stocks/VRX
Main Web Sites:
http://www.dailystockcharts.com/ AND http://www.stockmarketfunding.com/
MY GOOGLE +:
https://plus.google.com/u/0/107014460504455758500/about
Contact US:
http://www.dailystockcharts.com/contact-us/
- published: 21 Oct 2015
- views: 666
Valeant Pharmaceuticals Team 3
- Order: Reorder
- Duration: 2:48
- Updated: 04 Feb 2016
- views: 15
- published: 04 Feb 2016
- views: 15
Valeant Pharmaceuticals price gouge: Is Congress to blame? | World Finance
- Order: Reorder
- Duration: 4:57
- Updated: 22 Oct 2015
- views: 103
A political football is being punted over Valeant’s price hikes, but it will not be until after the election before a resolution is found, says William E. Rhode...
A political football is being punted over Valeant’s price hikes, but it will not be until after the election before a resolution is found, says William E. Rhodes, Founder and Chief Investment Strategist at Rhodes Analytics
For a full transcript visit: http://www.worldfinance.com/videos/valeant-pharmaceuticals-price-gouge-is-congress-to-blame
For more World Finance videos go to http://www.worldfinance.com/videos/
wn.com/Valeant Pharmaceuticals Price Gouge Is Congress To Blame | World Finance
A political football is being punted over Valeant’s price hikes, but it will not be until after the election before a resolution is found, says William E. Rhodes, Founder and Chief Investment Strategist at Rhodes Analytics
For a full transcript visit: http://www.worldfinance.com/videos/valeant-pharmaceuticals-price-gouge-is-congress-to-blame
For more World Finance videos go to http://www.worldfinance.com/videos/
- published: 22 Oct 2015
- views: 103
Horizon Pharma CEO: Not A Mini-Valeant | Mad Money | CNBC
- Order: Reorder
- Duration: 7:05
- Updated: 10 Nov 2015
- views: 1100
Its stock has been crushed lately thanks to Valeant comparisons. After its latest earnings, does the market have it all wrong?
» Subscribe to CNBC: http://cnb.c...
Its stock has been crushed lately thanks to Valeant comparisons. After its latest earnings, does the market have it all wrong?
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about Horizon Pharma here: http://cnb.cx/1klPXnI
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
Horizon Pharma CEO: Not A Mini-Valeant | Mad Money | CNBC
wn.com/Horizon Pharma Ceo Not A Mini Valeant | Mad Money | Cnbc
Its stock has been crushed lately thanks to Valeant comparisons. After its latest earnings, does the market have it all wrong?
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about Horizon Pharma here: http://cnb.cx/1klPXnI
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
Horizon Pharma CEO: Not A Mini-Valeant | Mad Money | CNBC
- published: 10 Nov 2015
- views: 1100
[470] The Valeant scandal and Steve Keen on China and Portugal
- Order: Reorder
- Duration: 27:53
- Updated: 05 Nov 2015
- views: 6289
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow an...
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow and will slow even further. Ameera David weighs in. Ameera also highlights a new smart Gmail feature that will be able to scan your email and offer quick replies. Then, Ameera and RT correspondent Manuel Rapalo update their earlier discussion on Airbnb’s fight in to stay legal in San Francisco and discuss Expedia’s $3.9 billion deal to buy Airbnb competitor HomeAway. Afterwards, Paul Craig Roberts gives us his take on the elimination of two popular social security claiming measures, part of his interview with Boom Bust’s Bianca Facchinei that will air Friday.
After the break, Boom Bust’s Edward Harrison sits down with Steve Keen, head of economics, history, and politics at Kingston University to get his thoughts on the path forward for China, emerging markets, and the global economy, as well as to assess whether politics in Portugal are radicalizing. And in The Big Deal, Ameera and Edward Harrison talk about the scandal surrounding former stock darling Valeant Pharmaceuticals.
Check us out on Facebook -- and feel free to ask us questions:
http://www.facebook.com/BoomBustRT
https://www.facebook.com/harrison.writedowns
https://www.facebook.com/erinade2020
https://www.facebook.com/biancafacch
Follow us @
https://twitter.com/AmeeraDavid
http://twitter.com/ErinAde
http://twitter.com/edwardnh\
https://twitter.com/BiancaFacchinei
wn.com/470 The Valeant Scandal And Steve Keen On China And Portugal
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow and will slow even further. Ameera David weighs in. Ameera also highlights a new smart Gmail feature that will be able to scan your email and offer quick replies. Then, Ameera and RT correspondent Manuel Rapalo update their earlier discussion on Airbnb’s fight in to stay legal in San Francisco and discuss Expedia’s $3.9 billion deal to buy Airbnb competitor HomeAway. Afterwards, Paul Craig Roberts gives us his take on the elimination of two popular social security claiming measures, part of his interview with Boom Bust’s Bianca Facchinei that will air Friday.
After the break, Boom Bust’s Edward Harrison sits down with Steve Keen, head of economics, history, and politics at Kingston University to get his thoughts on the path forward for China, emerging markets, and the global economy, as well as to assess whether politics in Portugal are radicalizing. And in The Big Deal, Ameera and Edward Harrison talk about the scandal surrounding former stock darling Valeant Pharmaceuticals.
Check us out on Facebook -- and feel free to ask us questions:
http://www.facebook.com/BoomBustRT
https://www.facebook.com/harrison.writedowns
https://www.facebook.com/erinade2020
https://www.facebook.com/biancafacch
Follow us @
https://twitter.com/AmeeraDavid
http://twitter.com/ErinAde
http://twitter.com/edwardnh\
https://twitter.com/BiancaFacchinei
- published: 05 Nov 2015
- views: 6289
Valeant Pharmaceuticals CEO Returns, But Company Postpones Release of Q4 Results
- Order: Reorder
- Duration: 1:13
- Updated: 29 Feb 2016
- views: 16
U.S. stocks opened slightly lower on Monday as Chinese officials intervened to prop up its slowing economy. China’s yuan was devalued to a three-week low and th...
U.S. stocks opened slightly lower on Monday as Chinese officials intervened to prop up its slowing economy. China’s yuan was devalued to a three-week low and the world’s second largest economy also cut the amount of money banks are required to maintain on reserve. 'Real activity [in China] continues to slow - and indeed that's broadly the picture in global emerging markets,’ said Michael Ingram, a market strategist with BGC Partners, based in London. Meanwhile, Valeant Pharmaceuticals (VRX) CEO Michael Pearson is returning to the company. He was out for over two months with pneumonia. Valeant was also supposed to release its fourth quarter results on Monday, but has postponed them to an undisclosed date. Finally, Starbucks (SBUX) is coming to Italy. The global coffee giant opens its first store next year in Milan. Starbucks is already in 67 countries worldwide. TheStreet’s Scott Gamm reports from Wall Street.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
wn.com/Valeant Pharmaceuticals Ceo Returns, But Company Postpones Release Of Q4 Results
U.S. stocks opened slightly lower on Monday as Chinese officials intervened to prop up its slowing economy. China’s yuan was devalued to a three-week low and the world’s second largest economy also cut the amount of money banks are required to maintain on reserve. 'Real activity [in China] continues to slow - and indeed that's broadly the picture in global emerging markets,’ said Michael Ingram, a market strategist with BGC Partners, based in London. Meanwhile, Valeant Pharmaceuticals (VRX) CEO Michael Pearson is returning to the company. He was out for over two months with pneumonia. Valeant was also supposed to release its fourth quarter results on Monday, but has postponed them to an undisclosed date. Finally, Starbucks (SBUX) is coming to Italy. The global coffee giant opens its first store next year in Milan. Starbucks is already in 67 countries worldwide. TheStreet’s Scott Gamm reports from Wall Street.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
- published: 29 Feb 2016
- views: 16
-
FirstWord Pharma Daily News Round-Up Video for March 15, 2016
The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day. Today's video highlights include Valeant Pharmaceuticals, Eli Lilly, solanezumab, Express Scripts, Roche, Blueprint Medicines, Celator Pharmaceuticals and Vyxeos. -
What's Ahead Tuesday: Drugmaker Reports Quarterly Earnings
In 'What's Ahead on Wall Street' for Tuesday Mar. 15, the companies we're following for earnings are DSW (DSW) and Valeant Pharmaceuticals (VRX) in the morning. Then in the afternoon, we get results from Oracle (ORCL). Valeant has been making headlines recently. Shares have gotten hammered as the company faces federal investigations. Investors are also worried about the company's focus going forward. On top of this, politicians have been taking jabs at the company for boosting drug prices. Given these challenges, Wall Street is expecting both the top and bottom line to decline from a year ago. For the recent quarter, it's looking for earnings of $2.61 a share on revenue of $2.75 billion. Investors will also get a few economic reports, but ut all eyes will be on the Fed as it starts its two... -
Encuentro digital con Ricardo González (14/03/2016)
Encuentro digital con Ricardo González (14/03/2016) Temas tratados: Ibex, S&P; 500, Banque Cantonale Vaudoise (Suiza), Sherwin-Williams Co/The (USA - 288), Microsoft (USA), Sysco Corp (USA), Trinseo Sa (USA), Premium Brands Holding (Canadá), Yahoo (USA), Valeant Pharmaceuticals International Inc (USA), Vestas Wind Systems (Dinamarca), Dr Pepper Snapple Group (USA), -
Substantial uncertainty with Valeant: Analyst Friday, 4 Mar 2016 | 5:16 PM ET
Dimitry Khmelnitsky, Veritas Investment research analyst, sticks with a sell rating for Valeant Pharmaceuticals and explains why the stock is not invest worthy. -
Hurt by Valeant, Mylan Stock Could Rise 30%.
http://www.barrons.com/articles/hurt-by-valeant-mylan-stock-could-rise-30-1457150042?mod=BOL_hp_mag Hurt by Valeant, Mylan Stock Could Rise 30%. The stock market is going all Valeant on Mylan. That’s a buying opportunity for value investors. Look for Mylan shares to rebound more than 30% over the next year. Valeant Pharmaceuticals International (ticker: VRX), down 73% over the past nine months, has drawn public scorn for its history of buying drugs and quickly raising prices. That doesn’t exactly describe Mylan (MYL), which last year collected 87% of its revenue and 79% of... Visit CHAOS View Archive For More CHAOS NEWS: https://www.youtube.com/channel/UCUiFq-IUU64l62ygPdbVnIA -
Valeant Pharmaceuticals dumps under $60 per share
Tuesday March 1st $VRX dropped below $60 for a quick few seconds after news leaked stating they were under an SEC Investigation. The following video Depicts this. -
Valeant shares slide on news of probe by U.S. SEC
(Reuters) - Shares in Valeant Pharmaceuticals International Inc fell as much as 21 percent on Monday after the drugmaker revealed that it was under investigation by the U.S. Securities and Exchange Commission. -
U.S. Securities and Exchange Commission investigating Valeant Pharmaceuticals
LAVAL, Que. Valeant Pharmaceuticals said Monday it is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe. -
Valeant shares drop as CEO returns, cancels earnings report
REUTERS: Shares in embattled drugmaker Valeant Pharmaceuticals International Inc fell 9 percent on Monday a day after the company said its chief executive officer had returned from medical leave, canceled the release of fourth-quarter earnings, and withdrew 2016 financial guidance. -
-
Are Analysts Bullish Valeant Pharmaceuticals Intl Inc (NYSE:VRX) After Last Week?
Out of 22 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 13 rate it cBuyd, 1 cSelld, while 8 cHoldd. This means 59% are positive. Valeant Pharmaceuticals Intl was the topic in 50 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Below is a list of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) latest ratings and price target changes. -
Valeant's stock plunges 18 pct as company's headaches mount
Valeant Pharmaceuticals' stock tanked Monday amid ongoing turmoil over the embattled drugmaker's delayed financial results, its leader's health and government probes into what has gone wrong at the Canadian company. -
Valeant Says It's Under Investigation by SEC
Feb. 29 -- Valeant Pharmaceuticals International Inc. is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe, the company said. Like this video? Subscribe to Bloomberg Business on YouTube: http://www.youtube.com/Bloomberg Watch Bloomberg TV live at http://www.bloomberg.com/live -
Valeant CEO Pearson to Return to Work after Long Illness
Valeant Pharmaceuticals says its CEO, J. Michael Pearson, will be returning to work after recovering from severe pneumonia. -
Valeant Pharmaceuticals Intl Inc.: 3 More Game-Changing Updates
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shocked the markets once again on Monday with a press release containing three interesting updates. -
Valeant CEO returns from medical leave of absence
NEW YORK (CNNMoney) J. Michael Pearson has returned to embattled drugmaker Valeant Pharmaceuticals as CEO after recovering from illness, the company said. -
Valeant delays Q4 report, gives CEO time to prepare as he returns from illness
MONTREAL - The return of Valeant Pharmaceuticals' chief executive from medical leave on the weekend has delayed the company's fourth-quarter financial report, which was to be released Monday. -
Valeant Welcomes Back CEO After Medical Leave, Splits Role To Appoint New Chairman
Valeant Pharmaceuticals (NYSE: VRX) International is set to welcome back CEO Michael Pearson after he returns from medical leave. However, some changes are in the works for the Chairman and CEO who had made headlines for his controversial but effective breakthrough strategies. -
The First Take – A tale of two CEOs
Editors Simon King and Matthew Dennis discuss Michael Pearson's return to Valeant Pharmaceuticals and rumours that GlaxoSmithKline is looking for Andrew Witty’s successor. -
FirstWord Pharma Daily News Round-Up Video for February 29, 2016
The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day. Today's video highlights include Valeant Pharmaceuticals, GlaxoSmithKline, Roche, lebrikizumab, AstraZeneca, China Medical System, Plendil and Imdur.
FirstWord Pharma Daily News Round-Up Video for March 15, 2016
- Order: Reorder
- Duration: 2:26
- Updated: 15 Mar 2016
- views: 5
The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day...
The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day. Today's video highlights include Valeant Pharmaceuticals, Eli Lilly, solanezumab, Express Scripts, Roche, Blueprint Medicines, Celator Pharmaceuticals and Vyxeos.
wn.com/Firstword Pharma Daily News Round Up Video For March 15, 2016
The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day. Today's video highlights include Valeant Pharmaceuticals, Eli Lilly, solanezumab, Express Scripts, Roche, Blueprint Medicines, Celator Pharmaceuticals and Vyxeos.
- published: 15 Mar 2016
- views: 5
What's Ahead Tuesday: Drugmaker Reports Quarterly Earnings
- Order: Reorder
- Duration: 1:43
- Updated: 15 Mar 2016
- views: 80
In 'What's Ahead on Wall Street' for Tuesday Mar. 15, the companies we're following for earnings are DSW (DSW) and Valeant Pharmaceuticals (VRX) in the morning....
In 'What's Ahead on Wall Street' for Tuesday Mar. 15, the companies we're following for earnings are DSW (DSW) and Valeant Pharmaceuticals (VRX) in the morning. Then in the afternoon, we get results from Oracle (ORCL). Valeant has been making headlines recently. Shares have gotten hammered as the company faces federal investigations. Investors are also worried about the company's focus going forward. On top of this, politicians have been taking jabs at the company for boosting drug prices. Given these challenges, Wall Street is expecting both the top and bottom line to decline from a year ago. For the recent quarter, it's looking for earnings of $2.61 a share on revenue of $2.75 billion. Investors will also get a few economic reports, but ut all eyes will be on the Fed as it starts its two-day meeting. Economists expect the Fed to sit tight on rates, but there could be more clues as to when the hikes will come. TheStreet's U-Jin Lee reports from New York.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
wn.com/What's Ahead Tuesday Drugmaker Reports Quarterly Earnings
In 'What's Ahead on Wall Street' for Tuesday Mar. 15, the companies we're following for earnings are DSW (DSW) and Valeant Pharmaceuticals (VRX) in the morning. Then in the afternoon, we get results from Oracle (ORCL). Valeant has been making headlines recently. Shares have gotten hammered as the company faces federal investigations. Investors are also worried about the company's focus going forward. On top of this, politicians have been taking jabs at the company for boosting drug prices. Given these challenges, Wall Street is expecting both the top and bottom line to decline from a year ago. For the recent quarter, it's looking for earnings of $2.61 a share on revenue of $2.75 billion. Investors will also get a few economic reports, but ut all eyes will be on the Fed as it starts its two-day meeting. Economists expect the Fed to sit tight on rates, but there could be more clues as to when the hikes will come. TheStreet's U-Jin Lee reports from New York.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
- published: 15 Mar 2016
- views: 80
Encuentro digital con Ricardo González (14/03/2016)
- Order: Reorder
- Duration: 31:05
- Updated: 14 Mar 2016
- views: 135
Encuentro digital con Ricardo González (14/03/2016)
Temas tratados: Ibex, S&P; 500, Banque Cantonale Vaudoise (Suiza), Sherwin-Williams Co/The (USA - 288), Micr...
Encuentro digital con Ricardo González (14/03/2016)
Temas tratados: Ibex, S&P; 500, Banque Cantonale Vaudoise (Suiza), Sherwin-Williams Co/The (USA - 288), Microsoft (USA), Sysco Corp (USA), Trinseo Sa (USA), Premium Brands Holding (Canadá), Yahoo (USA), Valeant Pharmaceuticals International Inc (USA), Vestas Wind Systems (Dinamarca), Dr Pepper Snapple Group (USA),
wn.com/Encuentro Digital Con Ricardo González (14 03 2016)
Encuentro digital con Ricardo González (14/03/2016)
Temas tratados: Ibex, S&P; 500, Banque Cantonale Vaudoise (Suiza), Sherwin-Williams Co/The (USA - 288), Microsoft (USA), Sysco Corp (USA), Trinseo Sa (USA), Premium Brands Holding (Canadá), Yahoo (USA), Valeant Pharmaceuticals International Inc (USA), Vestas Wind Systems (Dinamarca), Dr Pepper Snapple Group (USA),
- published: 14 Mar 2016
- views: 135
Substantial uncertainty with Valeant: Analyst Friday, 4 Mar 2016 | 5:16 PM ET
- Order: Reorder
- Duration: 4:51
- Updated: 06 Mar 2016
- views: 17
Dimitry Khmelnitsky, Veritas Investment research analyst, sticks with a sell rating for Valeant Pharmaceuticals and explains why the stock is not invest worthy....
Dimitry Khmelnitsky, Veritas Investment research analyst, sticks with a sell rating for Valeant Pharmaceuticals and explains why the stock is not invest worthy.
wn.com/Substantial Uncertainty With Valeant Analyst Friday, 4 Mar 2016 | 5 16 Pm Et
Dimitry Khmelnitsky, Veritas Investment research analyst, sticks with a sell rating for Valeant Pharmaceuticals and explains why the stock is not invest worthy.
- published: 06 Mar 2016
- views: 17
Hurt by Valeant, Mylan Stock Could Rise 30%.
- Order: Reorder
- Duration: 0:58
- Updated: 05 Mar 2016
- views: 16
http://www.barrons.com/articles/hurt-by-valeant-mylan-stock-could-rise-30-1457150042?mod=BOL_hp_mag
Hurt by Valeant, Mylan Stock Could Rise 30%.
The stock...
http://www.barrons.com/articles/hurt-by-valeant-mylan-stock-could-rise-30-1457150042?mod=BOL_hp_mag
Hurt by Valeant, Mylan Stock Could Rise 30%.
The stock market is going all Valeant on Mylan. That’s a buying opportunity for value investors. Look for Mylan shares to rebound more than 30% over the next year. Valeant Pharmaceuticals International (ticker: VRX), down 73% over the past nine months, has drawn public scorn for its history of buying drugs and quickly raising prices. That doesn’t exactly describe Mylan (MYL), which last year collected 87% of its revenue and 79% of...
Visit CHAOS View Archive For More CHAOS NEWS: https://www.youtube.com/channel/UCUiFq-IUU64l62ygPdbVnIA
wn.com/Hurt By Valeant, Mylan Stock Could Rise 30 .
http://www.barrons.com/articles/hurt-by-valeant-mylan-stock-could-rise-30-1457150042?mod=BOL_hp_mag
Hurt by Valeant, Mylan Stock Could Rise 30%.
The stock market is going all Valeant on Mylan. That’s a buying opportunity for value investors. Look for Mylan shares to rebound more than 30% over the next year. Valeant Pharmaceuticals International (ticker: VRX), down 73% over the past nine months, has drawn public scorn for its history of buying drugs and quickly raising prices. That doesn’t exactly describe Mylan (MYL), which last year collected 87% of its revenue and 79% of...
Visit CHAOS View Archive For More CHAOS NEWS: https://www.youtube.com/channel/UCUiFq-IUU64l62ygPdbVnIA
- published: 05 Mar 2016
- views: 16
Valeant Pharmaceuticals dumps under $60 per share
- Order: Reorder
- Duration: 3:30
- Updated: 02 Mar 2016
- views: 15
Tuesday March 1st $VRX dropped below $60 for a quick few seconds after news leaked stating they were under an SEC Investigation. The following video Depicts thi...
Tuesday March 1st $VRX dropped below $60 for a quick few seconds after news leaked stating they were under an SEC Investigation. The following video Depicts this.
wn.com/Valeant Pharmaceuticals Dumps Under 60 Per Share
Tuesday March 1st $VRX dropped below $60 for a quick few seconds after news leaked stating they were under an SEC Investigation. The following video Depicts this.
- published: 02 Mar 2016
- views: 15
Valeant shares slide on news of probe by U.S. SEC
- Order: Reorder
- Duration: 1:02
- Updated: 01 Mar 2016
- views: 0
(Reuters) - Shares in Valeant Pharmaceuticals International Inc fell as much as 21 percent on Monday after the drugmaker revealed that it was under investigatio...
(Reuters) - Shares in Valeant Pharmaceuticals International Inc fell as much as 21 percent on Monday after the drugmaker revealed that it was under investigation by the U.S. Securities and Exchange Commission.
wn.com/Valeant Shares Slide On News Of Probe By U.S. Sec
(Reuters) - Shares in Valeant Pharmaceuticals International Inc fell as much as 21 percent on Monday after the drugmaker revealed that it was under investigation by the U.S. Securities and Exchange Commission.
- published: 01 Mar 2016
- views: 0
U.S. Securities and Exchange Commission investigating Valeant Pharmaceuticals
- Order: Reorder
- Duration: 1:02
- Updated: 01 Mar 2016
- views: 0
LAVAL, Que. Valeant Pharmaceuticals said Monday it is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe.
LAVAL, Que. Valeant Pharmaceuticals said Monday it is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe.
wn.com/U.S. Securities And Exchange Commission Investigating Valeant Pharmaceuticals
LAVAL, Que. Valeant Pharmaceuticals said Monday it is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe.
- published: 01 Mar 2016
- views: 0
Valeant shares drop as CEO returns, cancels earnings report
- Order: Reorder
- Duration: 1:02
- Updated: 01 Mar 2016
- views: 0
REUTERS: Shares in embattled drugmaker Valeant Pharmaceuticals International Inc fell 9 percent on Monday a day after the company said its chief executive offic...
REUTERS: Shares in embattled drugmaker Valeant Pharmaceuticals International Inc fell 9 percent on Monday a day after the company said its chief executive officer had returned from medical leave, canceled the release of fourth-quarter earnings, and withdrew 2016 financial guidance.
wn.com/Valeant Shares Drop As Ceo Returns, Cancels Earnings Report
REUTERS: Shares in embattled drugmaker Valeant Pharmaceuticals International Inc fell 9 percent on Monday a day after the company said its chief executive officer had returned from medical leave, canceled the release of fourth-quarter earnings, and withdrew 2016 financial guidance.
- published: 01 Mar 2016
- views: 0
Valeant Pharmaceuticals Intl Inc (VRX) Stock Rating Reaffirmed by Mizuho
- Order: Reorder
- Duration: 1:02
- Updated: 01 Mar 2016
- views: 4
Valeant Pharmaceuticals Intl Inc (NYSE:VRX)s stock had its cneutrald rating reissued by Mizuho in a report issued on Monday, MarketBeat Ratings reports.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX)s stock had its cneutrald rating reissued by Mizuho in a report issued on Monday, MarketBeat Ratings reports.
wn.com/Valeant Pharmaceuticals Intl Inc (Vrx) Stock Rating Reaffirmed By Mizuho
Are Analysts Bullish Valeant Pharmaceuticals Intl Inc (NYSE:VRX) After Last Week?
- Order: Reorder
- Duration: 1:02
- Updated: 01 Mar 2016
- views: 2
Out of 22 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 13 rate it cBuyd, 1 cSelld, while 8 cHoldd. This means 59% are positive. Valeant Pharmaceut...
Out of 22 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 13 rate it cBuyd, 1 cSelld, while 8 cHoldd. This means 59% are positive. Valeant Pharmaceuticals Intl was the topic in 50 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Below is a list of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) latest ratings and price target changes.
wn.com/Are Analysts Bullish Valeant Pharmaceuticals Intl Inc (Nyse Vrx) After Last Week
Out of 22 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 13 rate it cBuyd, 1 cSelld, while 8 cHoldd. This means 59% are positive. Valeant Pharmaceuticals Intl was the topic in 50 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Below is a list of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) latest ratings and price target changes.
- published: 01 Mar 2016
- views: 2
Valeant's stock plunges 18 pct as company's headaches mount
- Order: Reorder
- Duration: 1:02
- Updated: 01 Mar 2016
- views: 0
Valeant Pharmaceuticals' stock tanked Monday amid ongoing turmoil over the embattled drugmaker's delayed financial results, its leader's health and government p...
Valeant Pharmaceuticals' stock tanked Monday amid ongoing turmoil over the embattled drugmaker's delayed financial results, its leader's health and government probes into what has gone wrong at the Canadian company.
wn.com/Valeant's Stock Plunges 18 Pct As Company's Headaches Mount
Valeant Pharmaceuticals' stock tanked Monday amid ongoing turmoil over the embattled drugmaker's delayed financial results, its leader's health and government probes into what has gone wrong at the Canadian company.
- published: 01 Mar 2016
- views: 0
Valeant Says It's Under Investigation by SEC
- Order: Reorder
- Duration: 2:17
- Updated: 01 Mar 2016
- views: 136
Feb. 29 -- Valeant Pharmaceuticals International Inc. is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe, t...
Feb. 29 -- Valeant Pharmaceuticals International Inc. is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe, the company said.
Like this video? Subscribe to Bloomberg Business on YouTube: http://www.youtube.com/Bloomberg
Watch Bloomberg TV live at http://www.bloomberg.com/live
wn.com/Valeant Says It's Under Investigation By Sec
Feb. 29 -- Valeant Pharmaceuticals International Inc. is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe, the company said.
Like this video? Subscribe to Bloomberg Business on YouTube: http://www.youtube.com/Bloomberg
Watch Bloomberg TV live at http://www.bloomberg.com/live
- published: 01 Mar 2016
- views: 136
Valeant CEO Pearson to Return to Work after Long Illness
- Order: Reorder
- Duration: 1:02
- Updated: 29 Feb 2016
- views: 1
Valeant Pharmaceuticals says its CEO, J. Michael Pearson, will be returning to work after recovering from severe pneumonia.
Valeant Pharmaceuticals says its CEO, J. Michael Pearson, will be returning to work after recovering from severe pneumonia.
wn.com/Valeant Ceo Pearson To Return To Work After Long Illness
Valeant Pharmaceuticals says its CEO, J. Michael Pearson, will be returning to work after recovering from severe pneumonia.
- published: 29 Feb 2016
- views: 1
Valeant Pharmaceuticals Intl Inc.: 3 More Game-Changing Updates
- Order: Reorder
- Duration: 1:02
- Updated: 29 Feb 2016
- views: 8
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shocked the markets once again on Monday with a press release containing three interesting updates.
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shocked the markets once again on Monday with a press release containing three interesting updates.
wn.com/Valeant Pharmaceuticals Intl Inc. 3 More Game Changing Updates
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shocked the markets once again on Monday with a press release containing three interesting updates.
- published: 29 Feb 2016
- views: 8
Valeant CEO returns from medical leave of absence
- Order: Reorder
- Duration: 1:02
- Updated: 29 Feb 2016
- views: 1
NEW YORK (CNNMoney) J. Michael Pearson has returned to embattled drugmaker Valeant Pharmaceuticals as CEO after recovering from illness, the company said.
NEW YORK (CNNMoney) J. Michael Pearson has returned to embattled drugmaker Valeant Pharmaceuticals as CEO after recovering from illness, the company said.
wn.com/Valeant Ceo Returns From Medical Leave Of Absence
NEW YORK (CNNMoney) J. Michael Pearson has returned to embattled drugmaker Valeant Pharmaceuticals as CEO after recovering from illness, the company said.
- published: 29 Feb 2016
- views: 1
Valeant delays Q4 report, gives CEO time to prepare as he returns from illness
- Order: Reorder
- Duration: 1:02
- Updated: 29 Feb 2016
- views: 0
MONTREAL - The return of Valeant Pharmaceuticals' chief executive from medical leave on the weekend has delayed the company's fourth-quarter financial report, w...
MONTREAL - The return of Valeant Pharmaceuticals' chief executive from medical leave on the weekend has delayed the company's fourth-quarter financial report, which was to be released Monday.
wn.com/Valeant Delays Q4 Report, Gives Ceo Time To Prepare As He Returns From Illness
MONTREAL - The return of Valeant Pharmaceuticals' chief executive from medical leave on the weekend has delayed the company's fourth-quarter financial report, which was to be released Monday.
- published: 29 Feb 2016
- views: 0
Valeant Welcomes Back CEO After Medical Leave, Splits Role To Appoint New Chairman
- Order: Reorder
- Duration: 1:02
- Updated: 29 Feb 2016
- views: 0
Valeant Pharmaceuticals (NYSE: VRX) International is set to welcome back CEO Michael Pearson after he returns from medical leave. However, some changes are in t...
Valeant Pharmaceuticals (NYSE: VRX) International is set to welcome back CEO Michael Pearson after he returns from medical leave. However, some changes are in the works for the Chairman and CEO who had made headlines for his controversial but effective breakthrough strategies.
wn.com/Valeant Welcomes Back Ceo After Medical Leave, Splits Role To Appoint New Chairman
Valeant Pharmaceuticals (NYSE: VRX) International is set to welcome back CEO Michael Pearson after he returns from medical leave. However, some changes are in the works for the Chairman and CEO who had made headlines for his controversial but effective breakthrough strategies.
- published: 29 Feb 2016
- views: 0
The First Take – A tale of two CEOs
- Order: Reorder
- Duration: 3:43
- Updated: 29 Feb 2016
- views: 14
Editors Simon King and Matthew Dennis discuss Michael Pearson's return to Valeant Pharmaceuticals and rumours that GlaxoSmithKline is looking for Andrew Witty’s...
Editors Simon King and Matthew Dennis discuss Michael Pearson's return to Valeant Pharmaceuticals and rumours that GlaxoSmithKline is looking for Andrew Witty’s successor.
wn.com/The First Take – A Tale Of Two Ceos
Editors Simon King and Matthew Dennis discuss Michael Pearson's return to Valeant Pharmaceuticals and rumours that GlaxoSmithKline is looking for Andrew Witty’s successor.
- published: 29 Feb 2016
- views: 14
FirstWord Pharma Daily News Round-Up Video for February 29, 2016
- Order: Reorder
- Duration: 2:03
- Updated: 29 Feb 2016
- views: 37
The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day...
The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day. Today's video highlights include Valeant Pharmaceuticals, GlaxoSmithKline, Roche, lebrikizumab, AstraZeneca, China Medical System, Plendil and Imdur.
wn.com/Firstword Pharma Daily News Round Up Video For February 29, 2016
The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day. Today's video highlights include Valeant Pharmaceuticals, GlaxoSmithKline, Roche, lebrikizumab, AstraZeneca, China Medical System, Plendil and Imdur.
- published: 29 Feb 2016
- views: 37
-
Как Правильно Покупать Анализировать Акции на Примере Valeant Pharmaceuticals VRX
Применение инструментов Provalue Analytics (PVA) на практике для экспресс анализа компании. Из закрытой конференции Provalue.club Будь на шаг впереди. Не позволяй брокеру манипулировать собой. Сэкономь недели на чтении годовых отчетов. Узнай о компании все за 15 минут использую PVA. Инструменты фундаментального анализа акций: http://analytics.provalue.club/ Сообщество Вэлью Инвесторов: http://provalue.club/ Учимся анализировать акции компании, как долю в бизнесе: http://value.provalue.ru Учимся использовать Опционные Стратегии: http://options.provalue.ru Дополнительно можете почитать тут: Вконтакт: http://vk.com/provalue Facebook: https://www.facebook.com/groups/provalue/ Инвестиционный Альманах: http://almanac.provalue.ru -
REALIST NEWS - Valeant plunges as report alleges Enron-like fraud
http://www.jmbullion.com (Recommended for Silver and Gold Purchases.) http://www.freespeak.net http://www.realistnews.net -
FNN: House Hearing on Drug Pricing - Martin Shkreli Refuses to Testify
(AP) - Pharmaceutical chief Martin Shkreli has arrived at a hearing where U.S. lawmakers want to hear from about severe hikes for a drug sold by a company that he acquired.But it's unlikely the former CEO of Turing Pharmaceuticals will answer questions in his appearance Thursday before the House Oversight and Government Reform Committee. Shkreli, widely scorned for hiking the price of a long-established and potentially lifesaving drug by more than 5,000 percent, has said he's exercising his Fifth Amendment right against self-incrimination. The 32-year-old Shkreli faces separate criminal charges of securities fraud related to another drug company. Also going before lawmakers is the interim CEO of Canada's largest drugmaker, Valeant Pharmaceuticals. Both companies have sharply raised prices... -
How To Build Value In The Drug Business
This year's two biggest pharma takeouts were Onyx Pharmaceuticals, purchased by Amgen for $10 BIllion, and Bausch + Lomb, a turnaround story sold to Valeant for $8.7 billion. The CEOs from both companies talk about how to revitalize a pharmaceutical firm. -
"Boom Bust" The Valeant scandal and Steve Keen on China and Portugal
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow and will slow even further. Ameera David weighs in. Ameera also highlights a new smart Gmail feature that will be able to scan your email and offer quick replies. Then, Ameera and RT correspondent Manuel Rapalo update their earlier discussion on Airbnb’s fight in to stay legal in San Francisco and discuss Expedia’s $3.9 billion deal to buy Airbnb competitor HomeAway. Afterwards, Paul Craig Roberts gives us his take on the elimination of two popular social security claiming measures, part of his interview with Boom Bust’s Bianca Facchinei that will air Friday. After the break, Boom Bust’s Edward Harrison sits down with Steve Keen, head... -
[142] Bryan Caplan on Parenting and George Selgin with more on Free Banking
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the crosshairs. Allergan released emails sent by a senior Morgan Stanley banker, which outwardly denigrated Valeant and its business strategy. Erin takes a look. Then, Erin talks to Bryan Caplan, a professor of economics at George Mason University, about the issue of nature vs nurture and childrearing. Then after, Erin brings you part two of her interview with Dr. George Selgin about free banking. Then, in today's Big Deal, Sam Sacks and Erin discuss the task economy and what it means for the future of the American labor market. Is it a good thing or not? Take a look. Check us out on Facebook: http://www.facebook.com/BoomBustRT https:... -
The Evolution of Specialty Pharma and Diagnostics
Moderator, Adele Oliva, Partner at Quaker Partners leads a panel discussion called The Evolution of Specialty Pharma and Diagnostics at the Healthcare Growth Cap Conference on April 11, 2013. Detailing the change in growth within this sector, panelists Patrick Heron of Frazier Healthcare, Bhaskar Chaudhuri of Valeant Pharmaceuticals and Frazier Healthcare, Samuel Saks of Jazz Pharmaceuticals, Martin Sobel of Marwood and Declan Quirke of Stifel, expand on the sectors continued evolution as a result of five key factors. View the complete Healthcare Growth Cap Conference agenda at http://growthcapcon.com/agenda/ -
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10-13-2015
Before the First Cup with Jules - TPP: Sovereignty Lost, DMCA Censorship & Big Pharma 10-8-2015 - https://www.youtube.com/watch?v=h38u_oCh3Pw The Final Leaked TPP Text Is All That We Feared - https://www.eff.org/deeplinks/2015/10/final-leaked-tpp-text-all-we-feared TPP Treaty: Intellectual Property Rights Chapter, Consolidated Text (October 5, 2015) - https://wikileaks.org/tpp-ip3/WikiLeaks-TPP-IP-Chapter/WikiLeaks-TPP-IP-Chapter-051015.pdf New Monsanto Spray Kills Bugs by Messing With Their Genes - http://www.motherjones.com/tom-philpott/2015/08/coming-farm-field-near-you-gene-silencing-pesticides-RNA-RNAi How the Trans-Pacific Partnership could drive up the cost of medicine worldwide - http://www.vox.com/2015/10/5/9454511/tpp-cost-medicine Valeant Pharmaceuticals CEO: We’re in Busi... -
Erin
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the . George Selgin is a Professor of Economics at the University of Georgia's Terry College of Business. He is a senior fellow at the Cato Institute. His research . -
Beauty and The Retail Beast: A Snapshot of Online Retailing and the Beauty Industry - SIC2012
Beauty Retail Panel Shauna Causey, Decide.com (Moderator) Alissa Hsu Lynch, Valeant Pharmaceuticals, Julie Johnston, drugstore.com, Eric Gottloeb, Walgreens Beauty and The Retail Beast: A Snapshot of Online Retailing and the Beauty Industry When you think of vertical categories that have thrived online and in the broader digital economy, things like books, music, ticket sales, and maybe even apparel come to-mind. But beauty products?? Counter-intuitive as it may seem, beauty-product retailers have been thriving for years: and many of the lessons and success factors can be applied to just about any online business or service. Get first-hand accounts from leaders from the online beauty industry—you may just come away with some beautiful new perspectives that can be applied almost univ... -
usa cinque
Beauty Retail Panel Shauna Causey, Decide.com (Moderator) Alissa Hsu Lynch, Valeant Pharmaceuticals, Julie Johnston, drugstore.com, Eric Gottloeb, . View More: . UnCommercial by Adbusters Virginia Lee, Senior Research Analyst at Euromonitor International, recently attended the HBA Global Expo. At HBA . -
Before the First Cup with Jules - Guinea Pigs, 21st Century Cures Act, Brain Fingerprints 10-14-15
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10-13-2015 - https://www.youtube.com/watch?v=7K276HLi1gU A path to 21st century cures - https://youtu.be/nv_wyTlfUDo 21st Century Cures: What You Need to Know - http://energycommerce.house.gov/cures 21st Century Cures Act: A huge step backward for FDA standards - http://www.healthnewsreview.org/2015/08/21st-century-cures-act-a-huge-step-backward-for-fda-standards/ Scientists are making progress on an exercise pill that mimics the effects of working out - http://www.sciencealert.com/scientists-are-making-progress-on-an-exercise-pill-that-mimics-the-effects-of-working-out Glyphosate’s Suppression of Cytochrome P450 Enzymes and Amino Acid Biosynthesis by the Gut Microbiome: Pathways to Modern Diseases... -
Boom Bust- Pharma Price Fixing?
Packed Show! The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow and will slow even further. Ameera David weighs in. Ameera also highlights a new smart Gmail feature that will be able to scan your email and offer quick replies. Then, Ameera and RT correspondent Manuel Rapalo update their earlier discussion on Airbnb’s fight in to stay legal in San Francisco and discuss Expedia’s $3.9 billion deal to buy Airbnb competitor HomeAway. Afterwards, Paul Craig Roberts gives us his take on the elimination of two popular social security claiming measures, part of his interview with Boom Bust’s Bianca Facchinei that will air Friday. After the break, Boom Bust’s Edward Harrison sits down with S... -
[135] Free Banking w/George Selgin & Ann Pettifor on Boom-Bust UK Economy
Our lead story: A new report by the Hass Institute at UC Berkley reveals that a one third of all mortgaged homes in the US are still underwater. According to the . Our lead story: On Wednesday the U-S Supreme Court struck down caps on political contributions that had previously been ruled constitutional by the Supreme . The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the . -
CHEX Daily - Monday Oct. 26, 2015
IN THE FIELD: THE YMCA of Peterborough’s is spinning for its’ #STRONGKIDS Fundraiser Campaign. Caley Bedore pops in for the 12-hour spinathon and checks in with a few like-minded volunteers. DAILY COPTALK: It started in 2014, and already an “offender management” program in City of Kawartha Lakes is showing some hopeful results. Sgt. Tom Hickey of The Kawartha Lakes Police Service explains what he’s watching for with the program. DAILY DOSE: Mona Younis, Doctor of Pharmacy, and why pharmacists are extremely busy today. Her message is definitely slanted, but it IS on behalf of the world of health & medicine! Plenty of information to come. DAILY CENTS: Andrew Pyle, Senior Wealth Advisor with ScotiaMcleod for Daily Cents is here just after 5:30 looking at the ongoing story of Valeant Pharm... -
Oct. 24th, 2015 Stockguy22 Saturday Morning Chart and Chat Webinar
Get Stockguy22 's Live Stock Buys/Sells in real time with charts and member videos only $69 /month https://members.stockguy22.com/signup/gold?coupon=GOLD69 Stockguy22 http://twitter.com/stockguy22 over 50,000 followers on twitter worldwide In today's webinar Stockguy22 Discussed recapped market charts : $INDU $SPY $COMPX $QQQ $IWM $UUP #oil #CRUDE #WTI Reminder FOMC meeting announcement this week Wed. Oct 28th, 2015 https://dl.dropboxusercontent.com/u/8806080/Oct26economicCalendar.jpg Economic Calendar http://stockguy22.com/daily-economic-calendar-earnings/ & lot of earnings important as catalyst this week and coming weeks so make sure stocks you own, are aware of earnings dates and/or expected earnings moves so you are not caught off guard. This coming week some key ones are AAPL... -
2012 Annual CEO Innovation, Brent Saunders - Bausch + Lomb
This is the 7th Annual CEO Innovation lecture hosted at Fairleigh Dickinson University. This year, CEO of Bausch & Lomb, Brent Saunders is invited to host the lecture and discuss his achievements and how innovation is changing the industry. Mr. Brenton L. Saunders, also known as Brent, J.D., has been the Chief Executive Officer and President of Forest Laboratories Inc. since October 1, 2013. Mr. Saunders served as an Advisor of Valeant Pharmaceuticals International, Inc. since August 2013. He served as Senior Vice President of Compliance, Legal and Regulatory at HomeCare America. Mr. Saunders served as the Chief Executive Officer of Bausch & Lomb Incorporated and Bausch & Lomb Holdings Incorporated since March 15, 2010. He served as a Special Adviser of General Atlantic LLC. From 2010 to ... -
2006 CEO Innovation Lecture Fred Hassan, Schering-Plough Corp.
Fred Hassan, Chairman of the Board and Chief Executive Officer, Schering-Plough Corporation spoke at Fairleigh Dickinson University. The 2006 CEO Innovation Lecture was held on February 23, 2006. Mr. Fred Hassan serves as the Managing Director, Managing Partner, and Partner at Warburg Pincus LLC. Mr. Hassan joined Warburg Pincus in 2009 and advises the Healthcare Group and provides strategic counsel across its portfolio. He serves as President of The International Federation of Pharmaceutical Manufacturers Association (IFPMA). He served as the Chairman and Chief Executive Officer of Schering-Plough Corporation since April 20, 2003 until November 3, 2009. He served as the President of Schering-Plough Corporation since April 2003. Mr. Hassan served as the Chairman of the Board of Pharmacia ... -
Juergen Frevert| Merz Pharmaceuticals GmbH | Germany | Dermatology 2014 | OMICS International
Title: Are botulinum toxin products different? 4th International Conference on Clinical & Experimental Dermatology April 14-16, 2014 San Antonio, USA OMICS International: http://omicsonline.org Vaccine Conferences: http://conferenceseries.com/immunology-conferences.php Global Medical Conferences: http://conferenceseries.com Global Pharmaceutical Conferences: http://pharmaceuticalconferences.com Global Cancer Conferences: http://cancersummit.org Global Diabetes Conferences: http://diabetesexpo.com Global Dental Conferences: http://dentalcongress.com Global Nursing Conferences: http://nursingconference.com Abstract Botulinum toxin type A products are widely use in aesthetic medicine e.g. in the treatment of glabellar lines. Three botulinum toxin type A products are marketed on the Eur... -
Как Правильно Покупать Анализировать Акции на Примере Valeant Pharmaceuticals VRX
- Order: Reorder
- Duration: 53:06
- Updated: 14 Dec 2015
- views: 93
Применение инструментов Provalue Analytics (PVA) на практике для экспресс анализа компании.
Из закрытой конференции Provalue.club
Будь на шаг впереди.
Не позвол...
Применение инструментов Provalue Analytics (PVA) на практике для экспресс анализа компании.
Из закрытой конференции Provalue.club
Будь на шаг впереди.
Не позволяй брокеру манипулировать собой.
Сэкономь недели на чтении годовых отчетов.
Узнай о компании все за 15 минут использую PVA.
Инструменты фундаментального анализа акций:
http://analytics.provalue.club/
Сообщество Вэлью Инвесторов:
http://provalue.club/
Учимся анализировать акции компании, как долю в бизнесе:
http://value.provalue.ru
Учимся использовать Опционные Стратегии:
http://options.provalue.ru
Дополнительно можете почитать тут:
Вконтакт: http://vk.com/provalue
Facebook: https://www.facebook.com/groups/provalue/
Инвестиционный Альманах: http://almanac.provalue.ru
wn.com/Как Правильно Покупать Анализировать Акции На Примере Valeant Pharmaceuticals Vrx
Применение инструментов Provalue Analytics (PVA) на практике для экспресс анализа компании.
Из закрытой конференции Provalue.club
Будь на шаг впереди.
Не позволяй брокеру манипулировать собой.
Сэкономь недели на чтении годовых отчетов.
Узнай о компании все за 15 минут использую PVA.
Инструменты фундаментального анализа акций:
http://analytics.provalue.club/
Сообщество Вэлью Инвесторов:
http://provalue.club/
Учимся анализировать акции компании, как долю в бизнесе:
http://value.provalue.ru
Учимся использовать Опционные Стратегии:
http://options.provalue.ru
Дополнительно можете почитать тут:
Вконтакт: http://vk.com/provalue
Facebook: https://www.facebook.com/groups/provalue/
Инвестиционный Альманах: http://almanac.provalue.ru
- published: 14 Dec 2015
- views: 93
REALIST NEWS - Valeant plunges as report alleges Enron-like fraud
- Order: Reorder
- Duration: 25:11
- Updated: 23 Oct 2015
- views: 4401
http://www.jmbullion.com (Recommended for Silver and Gold Purchases.)
http://www.freespeak.net
http://www.realistnews.net
http://www.jmbullion.com (Recommended for Silver and Gold Purchases.)
http://www.freespeak.net
http://www.realistnews.net
wn.com/Realist News Valeant Plunges As Report Alleges Enron Like Fraud
http://www.jmbullion.com (Recommended for Silver and Gold Purchases.)
http://www.freespeak.net
http://www.realistnews.net
- published: 23 Oct 2015
- views: 4401
FNN: House Hearing on Drug Pricing - Martin Shkreli Refuses to Testify
- Order: Reorder
- Duration: 146:22
- Updated: 04 Feb 2016
- views: 1856
(AP) - Pharmaceutical chief Martin Shkreli has arrived at a hearing where U.S. lawmakers want to hear from about severe hikes for a drug sold by a company that ...
(AP) - Pharmaceutical chief Martin Shkreli has arrived at a hearing where U.S. lawmakers want to hear from about severe hikes for a drug sold by a company that he acquired.But it's unlikely the former CEO of Turing Pharmaceuticals will answer questions in his appearance Thursday before the House Oversight and Government Reform Committee. Shkreli, widely scorned for hiking the price of a long-established and potentially lifesaving drug by more than 5,000 percent, has said he's exercising his Fifth Amendment right against self-incrimination. The 32-year-old Shkreli faces separate criminal charges of securities fraud related to another drug company. Also going before lawmakers is the interim CEO of Canada's largest drugmaker, Valeant Pharmaceuticals. Both companies have sharply raised prices for drugs taken by patients with heart problems, AIDS, cancer and other conditions.
wn.com/Fnn House Hearing On Drug Pricing Martin Shkreli Refuses To Testify
(AP) - Pharmaceutical chief Martin Shkreli has arrived at a hearing where U.S. lawmakers want to hear from about severe hikes for a drug sold by a company that he acquired.But it's unlikely the former CEO of Turing Pharmaceuticals will answer questions in his appearance Thursday before the House Oversight and Government Reform Committee. Shkreli, widely scorned for hiking the price of a long-established and potentially lifesaving drug by more than 5,000 percent, has said he's exercising his Fifth Amendment right against self-incrimination. The 32-year-old Shkreli faces separate criminal charges of securities fraud related to another drug company. Also going before lawmakers is the interim CEO of Canada's largest drugmaker, Valeant Pharmaceuticals. Both companies have sharply raised prices for drugs taken by patients with heart problems, AIDS, cancer and other conditions.
- published: 04 Feb 2016
- views: 1856
How To Build Value In The Drug Business
- Order: Reorder
- Duration: 24:59
- Updated: 18 Oct 2013
- views: 710
This year's two biggest pharma takeouts were Onyx Pharmaceuticals, purchased by Amgen for $10 BIllion, and Bausch + Lomb, a turnaround story sold to Valeant for...
This year's two biggest pharma takeouts were Onyx Pharmaceuticals, purchased by Amgen for $10 BIllion, and Bausch + Lomb, a turnaround story sold to Valeant for $8.7 billion. The CEOs from both companies talk about how to revitalize a pharmaceutical firm.
wn.com/How To Build Value In The Drug Business
This year's two biggest pharma takeouts were Onyx Pharmaceuticals, purchased by Amgen for $10 BIllion, and Bausch + Lomb, a turnaround story sold to Valeant for $8.7 billion. The CEOs from both companies talk about how to revitalize a pharmaceutical firm.
- published: 18 Oct 2013
- views: 710
"Boom Bust" The Valeant scandal and Steve Keen on China and Portugal
- Order: Reorder
- Duration: 26:19
- Updated: 06 Nov 2015
- views: 322
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow an...
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow and will slow even further. Ameera David weighs in. Ameera also highlights a new smart Gmail feature that will be able to scan your email and offer quick replies. Then, Ameera and RT correspondent Manuel Rapalo update their earlier discussion on Airbnb’s fight in to stay legal in San Francisco and discuss Expedia’s $3.9 billion deal to buy Airbnb competitor HomeAway. Afterwards, Paul Craig Roberts gives us his take on the elimination of two popular social security claiming measures, part of his interview with Boom Bust’s Bianca Facchinei that will air Friday.
After the break, Boom Bust’s Edward Harrison sits down with Steve Keen, head of economics, history, and politics at Kingston University to get his thoughts on the path forward for China, emerging markets, and the global economy, as well as to assess whether politics in Portugal are radicalizing. And in The Big Deal, Ameera and Edward Harrison talk about the scandal surrounding former stock darling Valeant Pharmaceuticals.
Recorded from RT, Boom Bust, November 6, 2015
wn.com/Boom Bust The Valeant Scandal And Steve Keen On China And Portugal
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow and will slow even further. Ameera David weighs in. Ameera also highlights a new smart Gmail feature that will be able to scan your email and offer quick replies. Then, Ameera and RT correspondent Manuel Rapalo update their earlier discussion on Airbnb’s fight in to stay legal in San Francisco and discuss Expedia’s $3.9 billion deal to buy Airbnb competitor HomeAway. Afterwards, Paul Craig Roberts gives us his take on the elimination of two popular social security claiming measures, part of his interview with Boom Bust’s Bianca Facchinei that will air Friday.
After the break, Boom Bust’s Edward Harrison sits down with Steve Keen, head of economics, history, and politics at Kingston University to get his thoughts on the path forward for China, emerging markets, and the global economy, as well as to assess whether politics in Portugal are radicalizing. And in The Big Deal, Ameera and Edward Harrison talk about the scandal surrounding former stock darling Valeant Pharmaceuticals.
Recorded from RT, Boom Bust, November 6, 2015
- published: 06 Nov 2015
- views: 322
[142] Bryan Caplan on Parenting and George Selgin with more on Free Banking
- Order: Reorder
- Duration: 27:26
- Updated: 17 Jun 2014
- views: 2133
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the cros...
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the crosshairs. Allergan released emails sent by a senior Morgan Stanley banker, which outwardly denigrated Valeant and its business strategy. Erin takes a look.
Then, Erin talks to Bryan Caplan, a professor of economics at George Mason University, about the issue of nature vs nurture and childrearing. Then after, Erin brings you part two of her interview with Dr. George Selgin about free banking.
Then, in today's Big Deal, Sam Sacks and Erin discuss the task economy and what it means for the future of the American labor market. Is it a good thing or not? Take a look.
Check us out on Facebook:
http://www.facebook.com/BoomBustRT
https://www.facebook.com/harrison.writedowns
https://www.facebook.com/erinade2020
Follow us @
http://twitter.com/ErinAde
http://twitter.com/edwardnh
wn.com/142 Bryan Caplan On Parenting And George Selgin With More On Free Banking
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the crosshairs. Allergan released emails sent by a senior Morgan Stanley banker, which outwardly denigrated Valeant and its business strategy. Erin takes a look.
Then, Erin talks to Bryan Caplan, a professor of economics at George Mason University, about the issue of nature vs nurture and childrearing. Then after, Erin brings you part two of her interview with Dr. George Selgin about free banking.
Then, in today's Big Deal, Sam Sacks and Erin discuss the task economy and what it means for the future of the American labor market. Is it a good thing or not? Take a look.
Check us out on Facebook:
http://www.facebook.com/BoomBustRT
https://www.facebook.com/harrison.writedowns
https://www.facebook.com/erinade2020
Follow us @
http://twitter.com/ErinAde
http://twitter.com/edwardnh
- published: 17 Jun 2014
- views: 2133
The Evolution of Specialty Pharma and Diagnostics
- Order: Reorder
- Duration: 52:12
- Updated: 22 May 2013
- views: 239
Moderator, Adele Oliva, Partner at Quaker Partners leads a panel discussion called The Evolution of Specialty Pharma and Diagnostics at the Healthcare Growth Ca...
Moderator, Adele Oliva, Partner at Quaker Partners leads a panel discussion called The Evolution of Specialty Pharma and Diagnostics at the Healthcare Growth Cap Conference on April 11, 2013. Detailing the change in growth within this sector, panelists Patrick Heron of Frazier Healthcare, Bhaskar Chaudhuri of Valeant Pharmaceuticals and Frazier Healthcare, Samuel Saks of Jazz Pharmaceuticals, Martin Sobel of Marwood and Declan Quirke of Stifel, expand on the sectors continued evolution as a result of five key factors.
View the complete Healthcare Growth Cap Conference agenda at http://growthcapcon.com/agenda/
wn.com/The Evolution Of Specialty Pharma And Diagnostics
Moderator, Adele Oliva, Partner at Quaker Partners leads a panel discussion called The Evolution of Specialty Pharma and Diagnostics at the Healthcare Growth Cap Conference on April 11, 2013. Detailing the change in growth within this sector, panelists Patrick Heron of Frazier Healthcare, Bhaskar Chaudhuri of Valeant Pharmaceuticals and Frazier Healthcare, Samuel Saks of Jazz Pharmaceuticals, Martin Sobel of Marwood and Declan Quirke of Stifel, expand on the sectors continued evolution as a result of five key factors.
View the complete Healthcare Growth Cap Conference agenda at http://growthcapcon.com/agenda/
- published: 22 May 2013
- views: 239
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10-13-2015
- Order: Reorder
- Duration: 59:48
- Updated: 13 Oct 2015
- views: 37
Before the First Cup with Jules - TPP: Sovereignty Lost, DMCA Censorship & Big Pharma 10-8-2015 - https://www.youtube.com/watch?v=h38u_oCh3Pw
The Final Leaked...
Before the First Cup with Jules - TPP: Sovereignty Lost, DMCA Censorship & Big Pharma 10-8-2015 - https://www.youtube.com/watch?v=h38u_oCh3Pw
The Final Leaked TPP Text Is All That We Feared - https://www.eff.org/deeplinks/2015/10/final-leaked-tpp-text-all-we-feared
TPP Treaty: Intellectual Property Rights Chapter, Consolidated Text (October 5, 2015) - https://wikileaks.org/tpp-ip3/WikiLeaks-TPP-IP-Chapter/WikiLeaks-TPP-IP-Chapter-051015.pdf
New Monsanto Spray Kills Bugs by Messing With Their Genes - http://www.motherjones.com/tom-philpott/2015/08/coming-farm-field-near-you-gene-silencing-pesticides-RNA-RNAi
How the Trans-Pacific Partnership could drive up the cost of medicine worldwide - http://www.vox.com/2015/10/5/9454511/tpp-cost-medicine
Valeant Pharmaceuticals CEO: We’re in Business of Shareholder Profit, not Helping the Sick - http://www.healthnutnews.com/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick
Drug Goes From $13.50 a Tablet to $750, Overnight - http://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html?_r=0
2013 Biologics Medicine in Development - http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf
Nestle Pays Only $524 to Extract 27,000,000 Gallons of California Drinking Water - http://theantimedia.org/nestle-pays-only-524-to-exract-27000000-gallons-of-california-drinking-water/
The Privatization of Water: Nestlé Denies that Water is a Fundamental Human Right - http://www.globalresearch.ca/the-privatisation-of-water-nestle-denies-that-water-is-a-fundamental-human-right/5332238
Understanding the Scientific Issues Embedded in the Generic Drug Approval Process - http://www.medscape.com/viewarticle/421495
Leading generic drug maker faked test results for FDA approval - http://www.cbsnews.com/news/leading-generic-drug-maker-faked-test-results-for-fda-approval/
Half of Congress Members Are Millionaires, Report Says - http://www.nytimes.com/2014/01/10/us/politics/more-than-half-the-members-of-congress-are-millionaires-analysis-finds.html?_r=0
The ‘placebo effect’ is getting even stronger with time, study finds - http://www.sciencealert.com/the-placebo-effect-is-somehow-getting-even-better-at-fooling-patients-study-finds
Study Underscores Power of Placebo Effect - http://www.webmd.com/brain/news/20150128/study-underscores-power-of-placebo-effect
Prayer and healing: A medical and scientific perspective on randomized controlled trials - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802370/
In first, scientists use sound waves to control brain cells - http://medicalxpress.com/news/2015-09-scientists-brain-cells.html
Dopamine Makes You Addicted To Seeking Information - https://www.psychologytoday.com/blog/brain-wise/201209/why-were-all-addicted-texts-twitter-and-google
Hidden addiction: Television - http://www.akademiai.com/doi/pdf/10.1556/JBA.2.2013.008
Kennedy brings anti-vaccine crusade to Albany - http://www.capitalnewyork.com/article/albany/2015/06/8569236/kennedy-brings-anti-vaccine-crusade-albany
How Americans Are Brainwashed to Fear Exactly the Wrong Things - http://www.alternet.org/fear-america/how-americans-are-brainwashed-fear-exactly-wrong-things
NDAA 2013: Congress approves domestic deceptive propaganda - https://www.rt.com/usa/propaganda-us-smith-amendment-903/
Giant March In Berlin Against Europe-U.S. Free Trade Deal - https://www.youtube.com/watch?v=HrEFfTvmNfQ
H.R.6 - 21st Century Cures Act - https://www.congress.gov/bill/114th-congress/house-bill/6
A path to 21st century cures - https://youtu.be/nv_wyTlfUDo
21st Century Cures Act: A huge step backward for FDA standards - http://www.healthnewsreview.org/2015/08/21st-century-cures-act-a-huge-step-backward-for-fda-standards/
DNA ‘vaccine’ sterilizes mice, could lead to one-shot birth control - http://news.sciencemag.org/biology/2015/10/dna-vaccine-sterilizes-mice-could-lead-one-shot-birth-control
Bill Gates is working on a single-dose, long-lasting contraceptive for women - http://www.sciencealert.com/bill-gates-is-working-on-a-single-dose-long-lasting-contraceptive-for-women
How the Male Birth-control Pill Will Work - http://health.howstuffworks.com/sexual-health/contraception/male-bc-pill1.htm
Scientists map genes that extend life by as much as 60 percent if deleted - http://www.sciencealert.com/scientists-map-genes-that-extend-life-by-as-much-as-60-percent-if-deleted
Five day 'fasting' diet slows down ageing and may add years to life - http://www.telegraph.co.uk/news/science/science-news/11683736/Five-day-fasting-diet-slows-down-ageing-and-may-add-years-to-life.html
Scientists are making progress on an exercise pill that mimics the effects of working out - http://www.sciencealert.com/scientists-are-making-progress-on-an-exercise-pill-that-mimics-the-effects-of-working-out
wn.com/Before The First Cup With Jules Big Pharma, Placebo Power, Dna Sterilization Vaccines 10 13 2015
Before the First Cup with Jules - TPP: Sovereignty Lost, DMCA Censorship & Big Pharma 10-8-2015 - https://www.youtube.com/watch?v=h38u_oCh3Pw
The Final Leaked TPP Text Is All That We Feared - https://www.eff.org/deeplinks/2015/10/final-leaked-tpp-text-all-we-feared
TPP Treaty: Intellectual Property Rights Chapter, Consolidated Text (October 5, 2015) - https://wikileaks.org/tpp-ip3/WikiLeaks-TPP-IP-Chapter/WikiLeaks-TPP-IP-Chapter-051015.pdf
New Monsanto Spray Kills Bugs by Messing With Their Genes - http://www.motherjones.com/tom-philpott/2015/08/coming-farm-field-near-you-gene-silencing-pesticides-RNA-RNAi
How the Trans-Pacific Partnership could drive up the cost of medicine worldwide - http://www.vox.com/2015/10/5/9454511/tpp-cost-medicine
Valeant Pharmaceuticals CEO: We’re in Business of Shareholder Profit, not Helping the Sick - http://www.healthnutnews.com/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick
Drug Goes From $13.50 a Tablet to $750, Overnight - http://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html?_r=0
2013 Biologics Medicine in Development - http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf
Nestle Pays Only $524 to Extract 27,000,000 Gallons of California Drinking Water - http://theantimedia.org/nestle-pays-only-524-to-exract-27000000-gallons-of-california-drinking-water/
The Privatization of Water: Nestlé Denies that Water is a Fundamental Human Right - http://www.globalresearch.ca/the-privatisation-of-water-nestle-denies-that-water-is-a-fundamental-human-right/5332238
Understanding the Scientific Issues Embedded in the Generic Drug Approval Process - http://www.medscape.com/viewarticle/421495
Leading generic drug maker faked test results for FDA approval - http://www.cbsnews.com/news/leading-generic-drug-maker-faked-test-results-for-fda-approval/
Half of Congress Members Are Millionaires, Report Says - http://www.nytimes.com/2014/01/10/us/politics/more-than-half-the-members-of-congress-are-millionaires-analysis-finds.html?_r=0
The ‘placebo effect’ is getting even stronger with time, study finds - http://www.sciencealert.com/the-placebo-effect-is-somehow-getting-even-better-at-fooling-patients-study-finds
Study Underscores Power of Placebo Effect - http://www.webmd.com/brain/news/20150128/study-underscores-power-of-placebo-effect
Prayer and healing: A medical and scientific perspective on randomized controlled trials - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802370/
In first, scientists use sound waves to control brain cells - http://medicalxpress.com/news/2015-09-scientists-brain-cells.html
Dopamine Makes You Addicted To Seeking Information - https://www.psychologytoday.com/blog/brain-wise/201209/why-were-all-addicted-texts-twitter-and-google
Hidden addiction: Television - http://www.akademiai.com/doi/pdf/10.1556/JBA.2.2013.008
Kennedy brings anti-vaccine crusade to Albany - http://www.capitalnewyork.com/article/albany/2015/06/8569236/kennedy-brings-anti-vaccine-crusade-albany
How Americans Are Brainwashed to Fear Exactly the Wrong Things - http://www.alternet.org/fear-america/how-americans-are-brainwashed-fear-exactly-wrong-things
NDAA 2013: Congress approves domestic deceptive propaganda - https://www.rt.com/usa/propaganda-us-smith-amendment-903/
Giant March In Berlin Against Europe-U.S. Free Trade Deal - https://www.youtube.com/watch?v=HrEFfTvmNfQ
H.R.6 - 21st Century Cures Act - https://www.congress.gov/bill/114th-congress/house-bill/6
A path to 21st century cures - https://youtu.be/nv_wyTlfUDo
21st Century Cures Act: A huge step backward for FDA standards - http://www.healthnewsreview.org/2015/08/21st-century-cures-act-a-huge-step-backward-for-fda-standards/
DNA ‘vaccine’ sterilizes mice, could lead to one-shot birth control - http://news.sciencemag.org/biology/2015/10/dna-vaccine-sterilizes-mice-could-lead-one-shot-birth-control
Bill Gates is working on a single-dose, long-lasting contraceptive for women - http://www.sciencealert.com/bill-gates-is-working-on-a-single-dose-long-lasting-contraceptive-for-women
How the Male Birth-control Pill Will Work - http://health.howstuffworks.com/sexual-health/contraception/male-bc-pill1.htm
Scientists map genes that extend life by as much as 60 percent if deleted - http://www.sciencealert.com/scientists-map-genes-that-extend-life-by-as-much-as-60-percent-if-deleted
Five day 'fasting' diet slows down ageing and may add years to life - http://www.telegraph.co.uk/news/science/science-news/11683736/Five-day-fasting-diet-slows-down-ageing-and-may-add-years-to-life.html
Scientists are making progress on an exercise pill that mimics the effects of working out - http://www.sciencealert.com/scientists-are-making-progress-on-an-exercise-pill-that-mimics-the-effects-of-working-out
- published: 13 Oct 2015
- views: 37
Erin
- Order: Reorder
- Duration: 46:36
- Updated: 11 Dec 2015
- views: 7
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the .
...
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the .
George Selgin is a Professor of Economics at the University of Georgia's Terry College of Business. He is a senior fellow at the Cato Institute. His research .
wn.com/Erin
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the .
George Selgin is a Professor of Economics at the University of Georgia's Terry College of Business. He is a senior fellow at the Cato Institute. His research .
- published: 11 Dec 2015
- views: 7
Beauty and The Retail Beast: A Snapshot of Online Retailing and the Beauty Industry - SIC2012
- Order: Reorder
- Duration: 50:32
- Updated: 28 Feb 2013
- views: 556
Beauty Retail Panel
Shauna Causey, Decide.com (Moderator)
Alissa Hsu Lynch, Valeant Pharmaceuticals,
Julie Johnston, drugstore.com,
Eric Gottloeb, Walgreens
B...
Beauty Retail Panel
Shauna Causey, Decide.com (Moderator)
Alissa Hsu Lynch, Valeant Pharmaceuticals,
Julie Johnston, drugstore.com,
Eric Gottloeb, Walgreens
Beauty and The Retail Beast: A Snapshot of Online Retailing and the Beauty Industry
When you think of vertical categories that have thrived online and in the broader digital economy, things like books, music, ticket sales, and maybe even apparel come to-mind. But beauty products?? Counter-intuitive as it may seem, beauty-product retailers have been thriving for years: and many of the lessons and success factors can be applied to just about any online business or service.
Get first-hand accounts from leaders from the online beauty industry—you may just come away with some beautiful new perspectives that can be applied almost universally. Learn how the beauty industry is leveraging their passionate communities in search, social and review sites to build brand loyalty and engagement.
wn.com/Beauty And The Retail Beast A Snapshot Of Online Retailing And The Beauty Industry Sic2012
Beauty Retail Panel
Shauna Causey, Decide.com (Moderator)
Alissa Hsu Lynch, Valeant Pharmaceuticals,
Julie Johnston, drugstore.com,
Eric Gottloeb, Walgreens
Beauty and The Retail Beast: A Snapshot of Online Retailing and the Beauty Industry
When you think of vertical categories that have thrived online and in the broader digital economy, things like books, music, ticket sales, and maybe even apparel come to-mind. But beauty products?? Counter-intuitive as it may seem, beauty-product retailers have been thriving for years: and many of the lessons and success factors can be applied to just about any online business or service.
Get first-hand accounts from leaders from the online beauty industry—you may just come away with some beautiful new perspectives that can be applied almost universally. Learn how the beauty industry is leveraging their passionate communities in search, social and review sites to build brand loyalty and engagement.
- published: 28 Feb 2013
- views: 556
usa cinque
- Order: Reorder
- Duration: 81:21
- Updated: 03 Dec 2015
- views: 13
Beauty Retail Panel Shauna Causey, Decide.com (Moderator) Alissa Hsu Lynch, Valeant Pharmaceuticals, Julie Johnston, drugstore.com, Eric Gottloeb, .
View Mor...
Beauty Retail Panel Shauna Causey, Decide.com (Moderator) Alissa Hsu Lynch, Valeant Pharmaceuticals, Julie Johnston, drugstore.com, Eric Gottloeb, .
View More: .
UnCommercial by Adbusters
Virginia Lee, Senior Research Analyst at Euromonitor International, recently attended the HBA Global Expo. At HBA .
wn.com/USA Cinque
Beauty Retail Panel Shauna Causey, Decide.com (Moderator) Alissa Hsu Lynch, Valeant Pharmaceuticals, Julie Johnston, drugstore.com, Eric Gottloeb, .
View More: .
UnCommercial by Adbusters
Virginia Lee, Senior Research Analyst at Euromonitor International, recently attended the HBA Global Expo. At HBA .
- published: 03 Dec 2015
- views: 13
Before the First Cup with Jules - Guinea Pigs, 21st Century Cures Act, Brain Fingerprints 10-14-15
- Order: Reorder
- Duration: 59:48
- Updated: 14 Oct 2015
- views: 16
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10-13-2015 - https://www.youtube.com/watch?v=7K276HLi1gU
A path to 21st...
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10-13-2015 - https://www.youtube.com/watch?v=7K276HLi1gU
A path to 21st century cures - https://youtu.be/nv_wyTlfUDo
21st Century Cures: What You Need to Know - http://energycommerce.house.gov/cures
21st Century Cures Act: A huge step backward for FDA standards - http://www.healthnewsreview.org/2015/08/21st-century-cures-act-a-huge-step-backward-for-fda-standards/
Scientists are making progress on an exercise pill that mimics the effects of working out - http://www.sciencealert.com/scientists-are-making-progress-on-an-exercise-pill-that-mimics-the-effects-of-working-out
Glyphosate’s Suppression of Cytochrome P450 Enzymes and Amino Acid Biosynthesis by the Gut Microbiome: Pathways to Modern Diseases - http://www.mdpi.com/1099-4300/15/4/1416
What You Eat Affects Your Genes: RNA from Rice Can Survive Digestion and Alter Gene Expression - http://blogs.discovermagazine.com/80beats/2011/09/21/what-you-eat-affects-your-genes-rna-from-rice-can-survive-digestion-and-alter-gene-expression
Before the First Cup with Jules - Edible GMO Vax in Rice & Lettuce, DNA, RNA, Gates, DARPA 9-16-2015 - https://www.youtube.com/watch?v=d8yMGC3CVcA
Bill Gates is working on a single-dose, long-lasting contraceptive for women - http://www.sciencealert.com/bill-gates-is-working-on-a-single-dose-long-lasting-contraceptive-for-women
Connections in the Brain, Like Fingerprints, Can Identify Individuals - http://blogs.discovermagazine.com/d-brief/2015/10/12/connections-in-the-brain-like-fingerprints-can-identify-individuals/
The Human Connectome Project - http://www.humanconnectomeproject.org/
You Now Have a Shorter Attention Span Than a Goldfish - http://time.com/3858309/attention-spans-goldfish/
ALPHABET HIRES DIRECTOR OF NATIONAL INSTITUTE OF MENTAL HEALTH - http://www.popsci.com/alphabet-hires-former-director-national-institute-mental-health
Brain Research through Advancing Innovative Neurotechnologies (BRAIN) - http://braininitiative.nih.gov/
U. S. Behavioral Insights Team - http://www.decisionsciencenews.com/2013/07/15/u-s-behavioral-insights-team/
Valeant Pharmaceuticals CEO: We’re in Business of Shareholder Profit, not Helping the Sick - http://www.healthnutnews.com/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick
UCY.TV is an investigative media platform, designed to give YOU a voice on the platform of your choice: Video, live radio, podcasts, written articles and more. UCY.TV's website offers visitors top-notch ORIGINAL alternative news from reputable journalists, investigative field reporters, insightful radio broadcasts, LIVE video streams, exclusive interviews, archives and an intelligent forum. To learn more about how to become a part of UCY and lend your voice to the growing alternative media movement, email: contact.ucytv@gmail.com. Real news, for the people, by the people.
wn.com/Before The First Cup With Jules Guinea Pigs, 21St Century Cures Act, Brain Fingerprints 10 14 15
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10-13-2015 - https://www.youtube.com/watch?v=7K276HLi1gU
A path to 21st century cures - https://youtu.be/nv_wyTlfUDo
21st Century Cures: What You Need to Know - http://energycommerce.house.gov/cures
21st Century Cures Act: A huge step backward for FDA standards - http://www.healthnewsreview.org/2015/08/21st-century-cures-act-a-huge-step-backward-for-fda-standards/
Scientists are making progress on an exercise pill that mimics the effects of working out - http://www.sciencealert.com/scientists-are-making-progress-on-an-exercise-pill-that-mimics-the-effects-of-working-out
Glyphosate’s Suppression of Cytochrome P450 Enzymes and Amino Acid Biosynthesis by the Gut Microbiome: Pathways to Modern Diseases - http://www.mdpi.com/1099-4300/15/4/1416
What You Eat Affects Your Genes: RNA from Rice Can Survive Digestion and Alter Gene Expression - http://blogs.discovermagazine.com/80beats/2011/09/21/what-you-eat-affects-your-genes-rna-from-rice-can-survive-digestion-and-alter-gene-expression
Before the First Cup with Jules - Edible GMO Vax in Rice & Lettuce, DNA, RNA, Gates, DARPA 9-16-2015 - https://www.youtube.com/watch?v=d8yMGC3CVcA
Bill Gates is working on a single-dose, long-lasting contraceptive for women - http://www.sciencealert.com/bill-gates-is-working-on-a-single-dose-long-lasting-contraceptive-for-women
Connections in the Brain, Like Fingerprints, Can Identify Individuals - http://blogs.discovermagazine.com/d-brief/2015/10/12/connections-in-the-brain-like-fingerprints-can-identify-individuals/
The Human Connectome Project - http://www.humanconnectomeproject.org/
You Now Have a Shorter Attention Span Than a Goldfish - http://time.com/3858309/attention-spans-goldfish/
ALPHABET HIRES DIRECTOR OF NATIONAL INSTITUTE OF MENTAL HEALTH - http://www.popsci.com/alphabet-hires-former-director-national-institute-mental-health
Brain Research through Advancing Innovative Neurotechnologies (BRAIN) - http://braininitiative.nih.gov/
U. S. Behavioral Insights Team - http://www.decisionsciencenews.com/2013/07/15/u-s-behavioral-insights-team/
Valeant Pharmaceuticals CEO: We’re in Business of Shareholder Profit, not Helping the Sick - http://www.healthnutnews.com/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick
UCY.TV is an investigative media platform, designed to give YOU a voice on the platform of your choice: Video, live radio, podcasts, written articles and more. UCY.TV's website offers visitors top-notch ORIGINAL alternative news from reputable journalists, investigative field reporters, insightful radio broadcasts, LIVE video streams, exclusive interviews, archives and an intelligent forum. To learn more about how to become a part of UCY and lend your voice to the growing alternative media movement, email: contact.ucytv@gmail.com. Real news, for the people, by the people.
- published: 14 Oct 2015
- views: 16
Boom Bust- Pharma Price Fixing?
- Order: Reorder
- Duration: 27:16
- Updated: 09 Nov 2015
- views: 44
Packed Show!
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, gro...
Packed Show!
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow and will slow even further. Ameera David weighs in. Ameera also highlights a new smart Gmail feature that will be able to scan your email and offer quick replies. Then, Ameera and RT correspondent Manuel Rapalo update their earlier discussion on Airbnb’s fight in to stay legal in San Francisco and discuss Expedia’s $3.9 billion deal to buy Airbnb competitor HomeAway. Afterwards, Paul Craig Roberts gives us his take on the elimination of two popular social security claiming measures, part of his interview with Boom Bust’s Bianca Facchinei that will air Friday.
After the break, Boom Bust’s Edward Harrison sits down with Steve Keen, head of economics, history, and politics at Kingston University, to get his thoughts on the path forward for China, emerging markets and the global economy, as well as to assess whether politics in Portugal are radicalizing. And in The Big Deal, Ameera and Edward Harrison talk about the scandal surrounding former stock darling Valeant Pharmaceuticals.
Channel "RT TV"
https://www.rt.com/shows/boom-bust/321039-eu-cuts-gmail-feature/
wn.com/Boom Bust Pharma Price Fixing
Packed Show!
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the third year of consecutive growth for the European Union, growth is slow and will slow even further. Ameera David weighs in. Ameera also highlights a new smart Gmail feature that will be able to scan your email and offer quick replies. Then, Ameera and RT correspondent Manuel Rapalo update their earlier discussion on Airbnb’s fight in to stay legal in San Francisco and discuss Expedia’s $3.9 billion deal to buy Airbnb competitor HomeAway. Afterwards, Paul Craig Roberts gives us his take on the elimination of two popular social security claiming measures, part of his interview with Boom Bust’s Bianca Facchinei that will air Friday.
After the break, Boom Bust’s Edward Harrison sits down with Steve Keen, head of economics, history, and politics at Kingston University, to get his thoughts on the path forward for China, emerging markets and the global economy, as well as to assess whether politics in Portugal are radicalizing. And in The Big Deal, Ameera and Edward Harrison talk about the scandal surrounding former stock darling Valeant Pharmaceuticals.
Channel "RT TV"
https://www.rt.com/shows/boom-bust/321039-eu-cuts-gmail-feature/
- published: 09 Nov 2015
- views: 44
[135] Free Banking w/George Selgin & Ann Pettifor on Boom-Bust UK Economy
- Order: Reorder
- Duration: 46:57
- Updated: 12 Dec 2015
- views: 5
Our lead story: A new report by the Hass Institute at UC Berkley reveals that a one third of all mortgaged homes in the US are still underwater. According to th...
Our lead story: A new report by the Hass Institute at UC Berkley reveals that a one third of all mortgaged homes in the US are still underwater. According to the .
Our lead story: On Wednesday the U-S Supreme Court struck down caps on political contributions that had previously been ruled constitutional by the Supreme .
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the .
wn.com/135 Free Banking W George Selgin Ann Pettifor On Boom Bust UK Economy
Our lead story: A new report by the Hass Institute at UC Berkley reveals that a one third of all mortgaged homes in the US are still underwater. According to the .
Our lead story: On Wednesday the U-S Supreme Court struck down caps on political contributions that had previously been ruled constitutional by the Supreme .
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. But it was actually bankers at Morgan Stanley who wound up in the .
- published: 12 Dec 2015
- views: 5
CHEX Daily - Monday Oct. 26, 2015
- Order: Reorder
- Duration: 42:26
- Updated: 27 Oct 2015
- views: 126
IN THE FIELD:
THE YMCA of Peterborough’s is spinning for its’ #STRONGKIDS Fundraiser Campaign. Caley Bedore pops in for the 12-hour spinathon and checks in with...
IN THE FIELD:
THE YMCA of Peterborough’s is spinning for its’ #STRONGKIDS Fundraiser Campaign. Caley Bedore pops in for the 12-hour spinathon and checks in with a few like-minded volunteers.
DAILY COPTALK:
It started in 2014, and already an “offender management” program in City of Kawartha Lakes is showing some hopeful results. Sgt. Tom Hickey of The Kawartha Lakes Police Service explains what he’s watching for with the program.
DAILY DOSE:
Mona Younis, Doctor of Pharmacy, and why pharmacists are extremely busy today. Her message is definitely slanted, but it IS on behalf of the world of health & medicine! Plenty of information to come.
DAILY CENTS:
Andrew Pyle, Senior Wealth Advisor with ScotiaMcleod for Daily Cents is here just after 5:30 looking at the ongoing story of Valeant Pharma. True drama in the world of pharmaceuticals and the “largest company” in Canada…. or is it? They’ve been brought under fire for pricing issues, are denying that anything is wrong and at the same time, asking for an investigation. Andrew Pyle digs through the details to see where the story rests now.
And some of the team behind the eSeniors Summit returns, with Cathy Berges (Member, Ptbo Council on Aging / eSeniors Summit Planning Committee) and Steve Austrin, of Shaw Computer Systems. While you and I may enjoy the fall weather, those with limited mobility or without their own transportation see the change in seasons as a dramatic change in their social life and in their quality of life. We’ll get a few notes from Steve on how to use technology to make some dramatic impact to “winter blahs”.
wn.com/Chex Daily Monday Oct. 26, 2015
IN THE FIELD:
THE YMCA of Peterborough’s is spinning for its’ #STRONGKIDS Fundraiser Campaign. Caley Bedore pops in for the 12-hour spinathon and checks in with a few like-minded volunteers.
DAILY COPTALK:
It started in 2014, and already an “offender management” program in City of Kawartha Lakes is showing some hopeful results. Sgt. Tom Hickey of The Kawartha Lakes Police Service explains what he’s watching for with the program.
DAILY DOSE:
Mona Younis, Doctor of Pharmacy, and why pharmacists are extremely busy today. Her message is definitely slanted, but it IS on behalf of the world of health & medicine! Plenty of information to come.
DAILY CENTS:
Andrew Pyle, Senior Wealth Advisor with ScotiaMcleod for Daily Cents is here just after 5:30 looking at the ongoing story of Valeant Pharma. True drama in the world of pharmaceuticals and the “largest company” in Canada…. or is it? They’ve been brought under fire for pricing issues, are denying that anything is wrong and at the same time, asking for an investigation. Andrew Pyle digs through the details to see where the story rests now.
And some of the team behind the eSeniors Summit returns, with Cathy Berges (Member, Ptbo Council on Aging / eSeniors Summit Planning Committee) and Steve Austrin, of Shaw Computer Systems. While you and I may enjoy the fall weather, those with limited mobility or without their own transportation see the change in seasons as a dramatic change in their social life and in their quality of life. We’ll get a few notes from Steve on how to use technology to make some dramatic impact to “winter blahs”.
- published: 27 Oct 2015
- views: 126
Oct. 24th, 2015 Stockguy22 Saturday Morning Chart and Chat Webinar
- Order: Reorder
- Duration: 116:27
- Updated: 25 Oct 2015
- views: 149
Get Stockguy22 's Live Stock Buys/Sells in real time with charts and member videos only $69 /month https://members.stockguy22.com/signup/gold?coupon=GOLD69
Sto...
Get Stockguy22 's Live Stock Buys/Sells in real time with charts and member videos only $69 /month https://members.stockguy22.com/signup/gold?coupon=GOLD69
Stockguy22 http://twitter.com/stockguy22
over 50,000 followers on twitter worldwide
In today's webinar Stockguy22 Discussed
recapped market charts : $INDU $SPY $COMPX $QQQ $IWM $UUP #oil #CRUDE #WTI
Reminder FOMC meeting announcement this week Wed. Oct 28th, 2015
https://dl.dropboxusercontent.com/u/8806080/Oct26economicCalendar.jpg
Economic Calendar http://stockguy22.com/daily-economic-calendar-earnings/
& lot of earnings important as catalyst this week and coming weeks so make sure stocks you own, are aware of earnings dates and/or expected earnings moves so you are not caught off guard.
This coming week some key ones are AAPL , GPRO BABA GILD SCTY SBUX TEVA & many more
Earnings Oct 26-30th, 2015 - http://biz.yahoo.com/research/earncal/20151026.html
Chart requests & more charts for Saturday were: $AAPL $GPRO $VRX $BIIB $NFLX $GOOGL $GOOG $FB
Recapped the VRX options trade and the stock trade.
Recapped the chart and the covered calls i did against the position ahead of Monday's event which happens at 8amEST
What is the link to VRX ( Valeant Pharmaceutical ) call Monday ? The Valeant call will happen #premarket Monday Oct 26th @ 8amEST http://ir.valeant.com/investor-relations/events-and-presentations/Event-Details/2015/Valeant-Investor-Call/default.aspx … #ExpectVolatility & min $5-10+ or - move IMO
Enjoy the webinar and information provided
#mentoring
#mentors
#stockMentors
#stockMarketMentors
#StockMarketMentoring
#BusinessMentoring
#TradingMentoring
#TradeMentoring
#realestateMentoring
#BusinessMentors
#Mentorships
#Mentorship
#TradeCoaching
#StockMarketCoaching
follow Stockguy22 on twitter at: http://twitter.com/stockguy22
website at : http://stockguy22.coM
Get Stockguy22 's Live Stock Buys/Sells in real time with charts and member videos only $69 /month https://members.stockguy22.com/signup/gold?coupon=GOLD
wn.com/Oct. 24Th, 2015 Stockguy22 Saturday Morning Chart And Chat Webinar
Get Stockguy22 's Live Stock Buys/Sells in real time with charts and member videos only $69 /month https://members.stockguy22.com/signup/gold?coupon=GOLD69
Stockguy22 http://twitter.com/stockguy22
over 50,000 followers on twitter worldwide
In today's webinar Stockguy22 Discussed
recapped market charts : $INDU $SPY $COMPX $QQQ $IWM $UUP #oil #CRUDE #WTI
Reminder FOMC meeting announcement this week Wed. Oct 28th, 2015
https://dl.dropboxusercontent.com/u/8806080/Oct26economicCalendar.jpg
Economic Calendar http://stockguy22.com/daily-economic-calendar-earnings/
& lot of earnings important as catalyst this week and coming weeks so make sure stocks you own, are aware of earnings dates and/or expected earnings moves so you are not caught off guard.
This coming week some key ones are AAPL , GPRO BABA GILD SCTY SBUX TEVA & many more
Earnings Oct 26-30th, 2015 - http://biz.yahoo.com/research/earncal/20151026.html
Chart requests & more charts for Saturday were: $AAPL $GPRO $VRX $BIIB $NFLX $GOOGL $GOOG $FB
Recapped the VRX options trade and the stock trade.
Recapped the chart and the covered calls i did against the position ahead of Monday's event which happens at 8amEST
What is the link to VRX ( Valeant Pharmaceutical ) call Monday ? The Valeant call will happen #premarket Monday Oct 26th @ 8amEST http://ir.valeant.com/investor-relations/events-and-presentations/Event-Details/2015/Valeant-Investor-Call/default.aspx … #ExpectVolatility & min $5-10+ or - move IMO
Enjoy the webinar and information provided
#mentoring
#mentors
#stockMentors
#stockMarketMentors
#StockMarketMentoring
#BusinessMentoring
#TradingMentoring
#TradeMentoring
#realestateMentoring
#BusinessMentors
#Mentorships
#Mentorship
#TradeCoaching
#StockMarketCoaching
follow Stockguy22 on twitter at: http://twitter.com/stockguy22
website at : http://stockguy22.coM
Get Stockguy22 's Live Stock Buys/Sells in real time with charts and member videos only $69 /month https://members.stockguy22.com/signup/gold?coupon=GOLD
- published: 25 Oct 2015
- views: 149
2012 Annual CEO Innovation, Brent Saunders - Bausch + Lomb
- Order: Reorder
- Duration: 37:28
- Updated: 03 Oct 2013
- views: 687
This is the 7th Annual CEO Innovation lecture hosted at Fairleigh Dickinson University. This year, CEO of Bausch & Lomb, Brent Saunders is invited to host the l...
This is the 7th Annual CEO Innovation lecture hosted at Fairleigh Dickinson University. This year, CEO of Bausch & Lomb, Brent Saunders is invited to host the lecture and discuss his achievements and how innovation is changing the industry.
Mr. Brenton L. Saunders, also known as Brent, J.D., has been the Chief Executive Officer and President of Forest Laboratories Inc. since October 1, 2013. Mr. Saunders served as an Advisor of Valeant Pharmaceuticals International, Inc. since August 2013. He served as Senior Vice President of Compliance, Legal and Regulatory at HomeCare America. Mr. Saunders served as the Chief Executive Officer of Bausch & Lomb Incorporated and Bausch & Lomb Holdings Incorporated since March 15, 2010. He served as a Special Adviser of General Atlantic LLC. From 2010 to February 2013, he served as President of Bausch & Lomb Holdings Incorporated. He served as a Senior Executive of Schering-Plough from 2003 to 2010 and served as its President of Global Consumer Health Care. He served as Head of Integration for both Schering-Plough's merger with Merck & Co. He served as President of Consumer Health Care and Senior Vice President of Schering-Plough Corp. since February 2007. Mr. Saunders was responsible for leading the U.S. and Canadian Consumer Health Care business and works collaboratively with the Global Pharmaceutical Business unit. He served as Senior Vice President, Global Compliance and Business Practices of Schering-Plough Corp. from November 1, 2003 to February 20, 2007. He served as a Member of Executive Management Team (EMT) and the Operations Management Team (OMT) of Schering-Plough Corp. His responsibilities included the development of Global Standards, Training and Enforcement Programs for Compliance in all areas of Schering Plough Corp., including manufacturing, R&D; programs, clinical trials and sales and marketing. He was also responsible for the implementation of privacy policies for customers, patients, employees and other stakeholders. He has extensive experience negotiating and implementing corporate integrity agreements with state and federal agencies. He has significant healthcare industry expertise and led various business transformations and integrations. He has extensive knowledge of compliance, risk assessment, strategy and business development and extensive experience as an officer and director of public companies in the healthcare and pharmaceuticals industry. Mr. Saunders joined Schering-Plough from PricewaterhouseCoopers where he led its compliance business advisory services group. He was a Partner and Head of the Compliance Business Advisory Group at PricewaterhouseCoopers LLP from 2000 to 2003. He served as Chief Compliance Officer for Coventry Health Care and for Thomas Jefferson University and Health System. He was the co-founder and President of the Health Care Compliance Association. He serevd as Senior Vice President of Compliance, Legal, and Regulatory at Home Care Corp. of America. He served as Chief Risk Officer of Coventry Health Care from 1998 to 1999. He co-founded Health Care Compliance Association in 1995. He served as Chairman of the New York chapter of the American Heart Association. He also serves on the transition team for New Jersey Governor-Elect Chris Christie. In 1997, Mr. Saunders was named Compliance Officer of the Year at Health Care Compliance Association. Mr. Saunders has been a Director of Forest Laboratories Inc. since August 2011. He serves on the Boards of ElectroCore, LLC and the Overlook Hospital Foundation. He has been a Member of Upstate New York Regional Advisory Board at The Federal Reserve Bank of New York since June 9, 2010. He served as Director of Bausch & Lomb Holdings Incorporated and Bausch & Lomb Incorporated since March 15, 2010. He is a noted speaker on compliance and risk management issues in the health care industry, and also taught health law at Widener School of Law as an adjunct faculty Member. Mr. Saunders has a JD from the Temple University School of Law, an MBA from the Temple University School of Business and Management, and graduated with a BA in Economics from the University of Pittsburgh.
wn.com/2012 Annual Ceo Innovation, Brent Saunders Bausch Lomb
This is the 7th Annual CEO Innovation lecture hosted at Fairleigh Dickinson University. This year, CEO of Bausch & Lomb, Brent Saunders is invited to host the lecture and discuss his achievements and how innovation is changing the industry.
Mr. Brenton L. Saunders, also known as Brent, J.D., has been the Chief Executive Officer and President of Forest Laboratories Inc. since October 1, 2013. Mr. Saunders served as an Advisor of Valeant Pharmaceuticals International, Inc. since August 2013. He served as Senior Vice President of Compliance, Legal and Regulatory at HomeCare America. Mr. Saunders served as the Chief Executive Officer of Bausch & Lomb Incorporated and Bausch & Lomb Holdings Incorporated since March 15, 2010. He served as a Special Adviser of General Atlantic LLC. From 2010 to February 2013, he served as President of Bausch & Lomb Holdings Incorporated. He served as a Senior Executive of Schering-Plough from 2003 to 2010 and served as its President of Global Consumer Health Care. He served as Head of Integration for both Schering-Plough's merger with Merck & Co. He served as President of Consumer Health Care and Senior Vice President of Schering-Plough Corp. since February 2007. Mr. Saunders was responsible for leading the U.S. and Canadian Consumer Health Care business and works collaboratively with the Global Pharmaceutical Business unit. He served as Senior Vice President, Global Compliance and Business Practices of Schering-Plough Corp. from November 1, 2003 to February 20, 2007. He served as a Member of Executive Management Team (EMT) and the Operations Management Team (OMT) of Schering-Plough Corp. His responsibilities included the development of Global Standards, Training and Enforcement Programs for Compliance in all areas of Schering Plough Corp., including manufacturing, R&D; programs, clinical trials and sales and marketing. He was also responsible for the implementation of privacy policies for customers, patients, employees and other stakeholders. He has extensive experience negotiating and implementing corporate integrity agreements with state and federal agencies. He has significant healthcare industry expertise and led various business transformations and integrations. He has extensive knowledge of compliance, risk assessment, strategy and business development and extensive experience as an officer and director of public companies in the healthcare and pharmaceuticals industry. Mr. Saunders joined Schering-Plough from PricewaterhouseCoopers where he led its compliance business advisory services group. He was a Partner and Head of the Compliance Business Advisory Group at PricewaterhouseCoopers LLP from 2000 to 2003. He served as Chief Compliance Officer for Coventry Health Care and for Thomas Jefferson University and Health System. He was the co-founder and President of the Health Care Compliance Association. He serevd as Senior Vice President of Compliance, Legal, and Regulatory at Home Care Corp. of America. He served as Chief Risk Officer of Coventry Health Care from 1998 to 1999. He co-founded Health Care Compliance Association in 1995. He served as Chairman of the New York chapter of the American Heart Association. He also serves on the transition team for New Jersey Governor-Elect Chris Christie. In 1997, Mr. Saunders was named Compliance Officer of the Year at Health Care Compliance Association. Mr. Saunders has been a Director of Forest Laboratories Inc. since August 2011. He serves on the Boards of ElectroCore, LLC and the Overlook Hospital Foundation. He has been a Member of Upstate New York Regional Advisory Board at The Federal Reserve Bank of New York since June 9, 2010. He served as Director of Bausch & Lomb Holdings Incorporated and Bausch & Lomb Incorporated since March 15, 2010. He is a noted speaker on compliance and risk management issues in the health care industry, and also taught health law at Widener School of Law as an adjunct faculty Member. Mr. Saunders has a JD from the Temple University School of Law, an MBA from the Temple University School of Business and Management, and graduated with a BA in Economics from the University of Pittsburgh.
- published: 03 Oct 2013
- views: 687
2006 CEO Innovation Lecture Fred Hassan, Schering-Plough Corp.
- Order: Reorder
- Duration: 51:31
- Updated: 03 Oct 2013
- views: 421
Fred Hassan, Chairman of the Board and Chief Executive Officer, Schering-Plough Corporation spoke at Fairleigh Dickinson University. The 2006 CEO Innovation Lec...
Fred Hassan, Chairman of the Board and Chief Executive Officer, Schering-Plough Corporation spoke at Fairleigh Dickinson University. The 2006 CEO Innovation Lecture was held on February 23, 2006.
Mr. Fred Hassan serves as the Managing Director, Managing Partner, and Partner at Warburg Pincus LLC. Mr. Hassan joined Warburg Pincus in 2009 and advises the Healthcare Group and provides strategic counsel across its portfolio. He serves as President of The International Federation of Pharmaceutical Manufacturers Association (IFPMA). He served as the Chairman and Chief Executive Officer of Schering-Plough Corporation since April 20, 2003 until November 3, 2009. He served as the President of Schering-Plough Corporation since April 2003. Mr. Hassan served as the Chairman of the Board of Pharmacia Corporation from February 21, 2001 to 2003 and its Chief Executive Officer from March 2000 to 2003. He served as the Chief Executive Officer and President of Pharmacia & Upjohn Corporation from May 1997 to March 31, 2000. He served as an Executive Vice President of American Home Products Corp. (now Wyeth) from 1995 to May 1997, with responsibility for its pharmaceutical and medical products business. He served as a Senior Vice President from May 1993 to October 1995 and a group Vice President from March 1993 to May 1993. Mr. Hassan also served as the President of Wyeth-Ayerst Laboratories Division of American Home Products Corp. from 1989 to 1993. He served as the Chief Executive Officer, Chief Operating Officer, and Corporate Vice President of Sandoz Pharmaceuticals Corporation from 1984 to 1989, spent 17 years in it and headed its United States pharmaceuticals business. From 1972 to 1997, he served in various senior management roles at Novartis AG and other companies. He was the Chairman of Bausch & Lomb Holdings Incorporated since March 2010 and serves as its Director. He served as the Chairman of Bausch & Lomb Incorporated since March 2010 and as its Director since November 2009. He served as the Non-Executive Chairman of Avon Products Inc. from January 1, 2013 to April 26, 2013. Mr. Hassan has been an Independent Director of Time Warner Inc. since October 29, 2009. He serves as Director of Novo Nordisk. He has been a Director of Avon Products Inc. since 1999. He served as Lead Director at Avon Products since January 2011, and before that, served as its Presiding Director from 2007 to 2009. He served as a Director of Genetics Institute, LLC (formerly Wyeth Biopharma) from 1991 to 1996, and Pharmacia Corporation since March 31, 2000. Mr. Hassan also served as a Director of CIGNA Corp. from 2001 to 2003. He also served as the Director of Schering-Plough Corporation from April 22, 2003 to November 2009. He served as a Director of HP Enterprise Services, LLC (formerly Electronic Data Systems, LLC, Electronic Data Systems Corp.) from February 2003 to October 2003. He served as a Director of Pharmacia & Upjohn LLC from 1997 to 2000. He served as a Director of Valeant Pharmaceuticals International Inc from August 7, 2013 to May 20, 2014. Mr. Hassan also served as a Director of American Home Products Corporation from 1995 to May 1997. He served as the Chairman of The International Federation of Pharmaceutical Manufacturers Associations, The Pharmaceutical Research and Manufacturers of America (PhRMA), and the Healthcare Institute of New Jersey (HINJ). His book, "Reinvent, A Leader's Playbook for Serial Success," was published by Wiley in February 2013. Mr. Hassan received an M.B.A. from Harvard Business School and a B.S. degree in Chemical Engineering from the Imperial College of Science and Technology at the University of London
wn.com/2006 Ceo Innovation Lecture Fred Hassan, Schering Plough Corp.
Fred Hassan, Chairman of the Board and Chief Executive Officer, Schering-Plough Corporation spoke at Fairleigh Dickinson University. The 2006 CEO Innovation Lecture was held on February 23, 2006.
Mr. Fred Hassan serves as the Managing Director, Managing Partner, and Partner at Warburg Pincus LLC. Mr. Hassan joined Warburg Pincus in 2009 and advises the Healthcare Group and provides strategic counsel across its portfolio. He serves as President of The International Federation of Pharmaceutical Manufacturers Association (IFPMA). He served as the Chairman and Chief Executive Officer of Schering-Plough Corporation since April 20, 2003 until November 3, 2009. He served as the President of Schering-Plough Corporation since April 2003. Mr. Hassan served as the Chairman of the Board of Pharmacia Corporation from February 21, 2001 to 2003 and its Chief Executive Officer from March 2000 to 2003. He served as the Chief Executive Officer and President of Pharmacia & Upjohn Corporation from May 1997 to March 31, 2000. He served as an Executive Vice President of American Home Products Corp. (now Wyeth) from 1995 to May 1997, with responsibility for its pharmaceutical and medical products business. He served as a Senior Vice President from May 1993 to October 1995 and a group Vice President from March 1993 to May 1993. Mr. Hassan also served as the President of Wyeth-Ayerst Laboratories Division of American Home Products Corp. from 1989 to 1993. He served as the Chief Executive Officer, Chief Operating Officer, and Corporate Vice President of Sandoz Pharmaceuticals Corporation from 1984 to 1989, spent 17 years in it and headed its United States pharmaceuticals business. From 1972 to 1997, he served in various senior management roles at Novartis AG and other companies. He was the Chairman of Bausch & Lomb Holdings Incorporated since March 2010 and serves as its Director. He served as the Chairman of Bausch & Lomb Incorporated since March 2010 and as its Director since November 2009. He served as the Non-Executive Chairman of Avon Products Inc. from January 1, 2013 to April 26, 2013. Mr. Hassan has been an Independent Director of Time Warner Inc. since October 29, 2009. He serves as Director of Novo Nordisk. He has been a Director of Avon Products Inc. since 1999. He served as Lead Director at Avon Products since January 2011, and before that, served as its Presiding Director from 2007 to 2009. He served as a Director of Genetics Institute, LLC (formerly Wyeth Biopharma) from 1991 to 1996, and Pharmacia Corporation since March 31, 2000. Mr. Hassan also served as a Director of CIGNA Corp. from 2001 to 2003. He also served as the Director of Schering-Plough Corporation from April 22, 2003 to November 2009. He served as a Director of HP Enterprise Services, LLC (formerly Electronic Data Systems, LLC, Electronic Data Systems Corp.) from February 2003 to October 2003. He served as a Director of Pharmacia & Upjohn LLC from 1997 to 2000. He served as a Director of Valeant Pharmaceuticals International Inc from August 7, 2013 to May 20, 2014. Mr. Hassan also served as a Director of American Home Products Corporation from 1995 to May 1997. He served as the Chairman of The International Federation of Pharmaceutical Manufacturers Associations, The Pharmaceutical Research and Manufacturers of America (PhRMA), and the Healthcare Institute of New Jersey (HINJ). His book, "Reinvent, A Leader's Playbook for Serial Success," was published by Wiley in February 2013. Mr. Hassan received an M.B.A. from Harvard Business School and a B.S. degree in Chemical Engineering from the Imperial College of Science and Technology at the University of London
- published: 03 Oct 2013
- views: 421
Juergen Frevert| Merz Pharmaceuticals GmbH | Germany | Dermatology 2014 | OMICS International
- Order: Reorder
- Duration: 24:13
- Updated: 15 Jul 2015
- views: 77
Title: Are botulinum toxin products different?
4th International Conference on Clinical & Experimental Dermatology
April 14-16, 2014 San Antonio, USA
OMICS Int...
Title: Are botulinum toxin products different?
4th International Conference on Clinical & Experimental Dermatology
April 14-16, 2014 San Antonio, USA
OMICS International: http://omicsonline.org
Vaccine Conferences: http://conferenceseries.com/immunology-conferences.php
Global Medical Conferences: http://conferenceseries.com
Global Pharmaceutical Conferences: http://pharmaceuticalconferences.com
Global Cancer Conferences: http://cancersummit.org
Global Diabetes Conferences: http://diabetesexpo.com
Global Dental Conferences: http://dentalcongress.com
Global Nursing Conferences: http://nursingconference.com
Abstract
Botulinum toxin type A products are widely use in aesthetic medicine e.g. in the treatment of glabellar lines. Three botulinum toxin type A products are marketed on the European and US market: Botox (Allergan) is claimed to contain the purified 900 kD botulinum complex, Dysport (Medicis/Valeant/Ipsen) contains besides the 150 kD neurotoxin a different set of bacterial proteins. Apart from the 150 kD neurotoxin, there are no other bacterial proteins present in Xeomin. Different technical processes are used for the manufacturing of the products: Botox is produced by vacuum drying leaving a thin film as the final product whereas Dysport and Xeomin are produced by lyophilisation. Xeomin has demonstrated the highest stability allowing storage at room temperature whereas Botox and Dysport must be stored in the refrigerator. All products show a similar spread from the injected muscle provided that the dose is equivalent and the injection conditions are similar. Thus, the profile of adverse events should be comparable. Several head-to-head studies have demonstrated a 1:1 ratio between Botox and Xeomin confirmed in a recent Consensus paper. Although numerous studies are published with different ratios for Botox : Dysport a fixed ratio is not determined, yet. The load of bacterial proteins was claimed to have an impact on the immunogenic potential of the products. But it is not the protein load per se, it is the presence of complexing proteins in Botox and Dysport which influences the risk of an immune reaction..
Biography
Jürgen Frevert graduated in chemistry and got his PhD in Biochemistry at Philipps-University, Marburg, Germany. After a postdoctoral fellowship at the University of California, Berkeley, USA he had several research position in biotech companies where he developed an artificial human skin for transplantation on chronic wounds and burn wounds. In cooperation with Merz Pharmaceuticals he developed the pure botulinum toxin. He is now head of botulinum toxin research of Merz Pharmaceuticals GmbH, Potsdam, Germany.
wn.com/Juergen Frevert| Merz Pharmaceuticals Gmbh | Germany | Dermatology 2014 | Omics International
Title: Are botulinum toxin products different?
4th International Conference on Clinical & Experimental Dermatology
April 14-16, 2014 San Antonio, USA
OMICS International: http://omicsonline.org
Vaccine Conferences: http://conferenceseries.com/immunology-conferences.php
Global Medical Conferences: http://conferenceseries.com
Global Pharmaceutical Conferences: http://pharmaceuticalconferences.com
Global Cancer Conferences: http://cancersummit.org
Global Diabetes Conferences: http://diabetesexpo.com
Global Dental Conferences: http://dentalcongress.com
Global Nursing Conferences: http://nursingconference.com
Abstract
Botulinum toxin type A products are widely use in aesthetic medicine e.g. in the treatment of glabellar lines. Three botulinum toxin type A products are marketed on the European and US market: Botox (Allergan) is claimed to contain the purified 900 kD botulinum complex, Dysport (Medicis/Valeant/Ipsen) contains besides the 150 kD neurotoxin a different set of bacterial proteins. Apart from the 150 kD neurotoxin, there are no other bacterial proteins present in Xeomin. Different technical processes are used for the manufacturing of the products: Botox is produced by vacuum drying leaving a thin film as the final product whereas Dysport and Xeomin are produced by lyophilisation. Xeomin has demonstrated the highest stability allowing storage at room temperature whereas Botox and Dysport must be stored in the refrigerator. All products show a similar spread from the injected muscle provided that the dose is equivalent and the injection conditions are similar. Thus, the profile of adverse events should be comparable. Several head-to-head studies have demonstrated a 1:1 ratio between Botox and Xeomin confirmed in a recent Consensus paper. Although numerous studies are published with different ratios for Botox : Dysport a fixed ratio is not determined, yet. The load of bacterial proteins was claimed to have an impact on the immunogenic potential of the products. But it is not the protein load per se, it is the presence of complexing proteins in Botox and Dysport which influences the risk of an immune reaction..
Biography
Jürgen Frevert graduated in chemistry and got his PhD in Biochemistry at Philipps-University, Marburg, Germany. After a postdoctoral fellowship at the University of California, Berkeley, USA he had several research position in biotech companies where he developed an artificial human skin for transplantation on chronic wounds and burn wounds. In cooperation with Merz Pharmaceuticals he developed the pure botulinum toxin. He is now head of botulinum toxin research of Merz Pharmaceuticals GmbH, Potsdam, Germany.
- published: 15 Jul 2015
- views: 77
Developments in the Prescription Drug Market: Oversight
- Order: Reorder
- Duration: 338:14
- Updated: 04 Feb 2016
- views: 47938
close fullscreen
- Playlist
- Chat
close fullscreen
- Playlist
- Chat
4:10
Valeant Pharmaceuticals / Drug Price Profiteering
Canada based Valeant Pharmaceuticals price hikes of drugs long off patent has raised the i...
published: 30 Sep 2015
Valeant Pharmaceuticals / Drug Price Profiteering
Valeant Pharmaceuticals / Drug Price Profiteering
- Report rights infringement
- published: 30 Sep 2015
- views: 844
5:03
Bill Ackman defends Valeant
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, ...
published: 05 Nov 2015
Bill Ackman defends Valeant
Bill Ackman defends Valeant
- Report rights infringement
- published: 05 Nov 2015
- views: 3500
3:57
A Valeant Tug of War
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blo...
published: 02 Dec 2015
A Valeant Tug of War
A Valeant Tug of War
- Report rights infringement
- published: 02 Dec 2015
- views: 1355
3:52
Bill Ackman: There's a Lot of Misinformation on Drug Pricing
Oct. 6 -- Activist investor Bill Ackman talks drug pricing and the controversy around Vale...
published: 07 Oct 2015
Bill Ackman: There's a Lot of Misinformation on Drug Pricing
Bill Ackman: There's a Lot of Misinformation on Drug Pricing
- Report rights infringement
- published: 07 Oct 2015
- views: 4915
2:31
Valeant Pharmaceuticals in crosshairs of U.S. Congress
Quebec-based Valeant Pharmaceutical's price hikes of drugs long off patent has raised the ...
published: 30 Sep 2015
Valeant Pharmaceuticals in crosshairs of U.S. Congress
Valeant Pharmaceuticals in crosshairs of U.S. Congress
- Report rights infringement
- published: 30 Sep 2015
- views: 4351
7:22
Bulls & Bears: Valeant Pharmaceuticals
Valeant Pharmaceuticals is the largest pharmaceutical company in Canada, over $100 Billion...
published: 27 Jul 2015
Bulls & Bears: Valeant Pharmaceuticals
Bulls & Bears: Valeant Pharmaceuticals
- Report rights infringement
- published: 27 Jul 2015
- views: 778
3:47
Heard: Valeant Gives Investors Headaches
Embattled pharmaceutical giant Valeant gave investors a bit of headache as the company can...
published: 29 Feb 2016
Heard: Valeant Gives Investors Headaches
Heard: Valeant Gives Investors Headaches
- Report rights infringement
- published: 29 Feb 2016
- views: 73
3:14
Pharma CEO Admits: Our Business is Profit, Not Helping Sick People
–J. Michael Pearson, the CEO of Valeant Pharmaceuticals, admits that his business is all a...
published: 24 Oct 2015
Pharma CEO Admits: Our Business is Profit, Not Helping Sick People
Pharma CEO Admits: Our Business is Profit, Not Helping Sick People
- Report rights infringement
- published: 24 Oct 2015
- views: 4836
3:25
Valeant Calls Short Seller's Report 'Erroneous'
Oct. 21 -- Valeant Pharmaceuticals International Inc. called a short seller’s report that ...
published: 21 Oct 2015
Valeant Calls Short Seller's Report 'Erroneous'
Valeant Calls Short Seller's Report 'Erroneous'
- Report rights infringement
- published: 21 Oct 2015
- views: 1642
1:17
Valeant Pharmaceuticals Shares Tank on Weak Guidance
U.S. stocks slipped on Tuesday after some disappointing consumer data. February retail sal...
published: 15 Mar 2016
Valeant Pharmaceuticals Shares Tank on Weak Guidance
Valeant Pharmaceuticals Shares Tank on Weak Guidance
- Report rights infringement
- published: 15 Mar 2016
- views: 10
4:05
Citron Research Founder: What Valeant's Doing 'Sounds Illegal'
Oct. 26 -- Andrew Left, founder at Citron Research, discusses calls by Valeant Pharmaceuti...
published: 26 Oct 2015
Citron Research Founder: What Valeant's Doing 'Sounds Illegal'
Citron Research Founder: What Valeant's Doing 'Sounds Illegal'
- Report rights infringement
- published: 26 Oct 2015
- views: 2912
4:10
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
...
published: 15 Mar 2016
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 03-15-16
- Report rights infringement
- published: 15 Mar 2016
- views: 21
3:43
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
...
published: 04 Nov 2015
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
Valeant Pharmaceuticals International - VRX Stock Chart Technical Analysis for 11-04-15
- Report rights infringement
- published: 04 Nov 2015
- views: 596
24:01
Valeant Pharma Autopsy: Counting the Lost Billions
10 of the smartest investors in the world just lost sizable fortunes, in 2 months, on one ...
published: 19 Nov 2015
Valeant Pharma Autopsy: Counting the Lost Billions
Valeant Pharma Autopsy: Counting the Lost Billions
- Report rights infringement
- published: 19 Nov 2015
- views: 884
close fullscreen
- Playlist
- Chat
2:26
FirstWord Pharma Daily News Round-Up Video for March 15, 2016
The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical ...
published: 15 Mar 2016
FirstWord Pharma Daily News Round-Up Video for March 15, 2016
FirstWord Pharma Daily News Round-Up Video for March 15, 2016
- Report rights infringement
- published: 15 Mar 2016
- views: 5
1:43
What's Ahead Tuesday: Drugmaker Reports Quarterly Earnings
In 'What's Ahead on Wall Street' for Tuesday Mar. 15, the companies we're following for ea...
published: 15 Mar 2016
What's Ahead Tuesday: Drugmaker Reports Quarterly Earnings
What's Ahead Tuesday: Drugmaker Reports Quarterly Earnings
- Report rights infringement
- published: 15 Mar 2016
- views: 80
31:05
Encuentro digital con Ricardo González (14/03/2016)
Encuentro digital con Ricardo González (14/03/2016)
Temas tratados: Ibex, S&P; 500, Banque...
published: 14 Mar 2016
Encuentro digital con Ricardo González (14/03/2016)
Encuentro digital con Ricardo González (14/03/2016)
- Report rights infringement
- published: 14 Mar 2016
- views: 135
4:51
Substantial uncertainty with Valeant: Analyst Friday, 4 Mar 2016 | 5:16 PM ET
Dimitry Khmelnitsky, Veritas Investment research analyst, sticks with a sell rating for Va...
published: 06 Mar 2016
Substantial uncertainty with Valeant: Analyst Friday, 4 Mar 2016 | 5:16 PM ET
Substantial uncertainty with Valeant: Analyst Friday, 4 Mar 2016 | 5:16 PM ET
- Report rights infringement
- published: 06 Mar 2016
- views: 17
0:58
Hurt by Valeant, Mylan Stock Could Rise 30%.
http://www.barrons.com/articles/hurt-by-valeant-mylan-stock-could-rise-30-1457150042?mod=B...
published: 05 Mar 2016
Hurt by Valeant, Mylan Stock Could Rise 30%.
Hurt by Valeant, Mylan Stock Could Rise 30%.
- Report rights infringement
- published: 05 Mar 2016
- views: 16
3:30
Valeant Pharmaceuticals dumps under $60 per share
Tuesday March 1st $VRX dropped below $60 for a quick few seconds after news leaked stating...
published: 02 Mar 2016
Valeant Pharmaceuticals dumps under $60 per share
Valeant Pharmaceuticals dumps under $60 per share
- Report rights infringement
- published: 02 Mar 2016
- views: 15
1:02
Valeant shares slide on news of probe by U.S. SEC
(Reuters) - Shares in Valeant Pharmaceuticals International Inc fell as much as 21 percent...
published: 01 Mar 2016
Valeant shares slide on news of probe by U.S. SEC
Valeant shares slide on news of probe by U.S. SEC
- Report rights infringement
- published: 01 Mar 2016
- views: 0
1:02
U.S. Securities and Exchange Commission investigating Valeant Pharmaceuticals
LAVAL, Que. Valeant Pharmaceuticals said Monday it is under investigation by the U.S. Sec...
published: 01 Mar 2016
U.S. Securities and Exchange Commission investigating Valeant Pharmaceuticals
U.S. Securities and Exchange Commission investigating Valeant Pharmaceuticals
- Report rights infringement
- published: 01 Mar 2016
- views: 0
1:02
Valeant shares drop as CEO returns, cancels earnings report
REUTERS: Shares in embattled drugmaker Valeant Pharmaceuticals International Inc fell 9 pe...
published: 01 Mar 2016
Valeant shares drop as CEO returns, cancels earnings report
Valeant shares drop as CEO returns, cancels earnings report
- Report rights infringement
- published: 01 Mar 2016
- views: 0
1:02
Valeant Pharmaceuticals Intl Inc (VRX) Stock Rating Reaffirmed by Mizuho
Valeant Pharmaceuticals Intl Inc (NYSE:VRX)s stock had its cneutrald rating reissued by Mi...
published: 01 Mar 2016
Valeant Pharmaceuticals Intl Inc (VRX) Stock Rating Reaffirmed by Mizuho
Valeant Pharmaceuticals Intl Inc (VRX) Stock Rating Reaffirmed by Mizuho
- Report rights infringement
- published: 01 Mar 2016
- views: 4
1:02
Are Analysts Bullish Valeant Pharmaceuticals Intl Inc (NYSE:VRX) After Last Week?
Out of 22 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 13 rate it cBuyd, 1 c...
published: 01 Mar 2016
Are Analysts Bullish Valeant Pharmaceuticals Intl Inc (NYSE:VRX) After Last Week?
Are Analysts Bullish Valeant Pharmaceuticals Intl Inc (NYSE:VRX) After Last Week?
- Report rights infringement
- published: 01 Mar 2016
- views: 2
1:02
Valeant's stock plunges 18 pct as company's headaches mount
Valeant Pharmaceuticals' stock tanked Monday amid ongoing turmoil over the embattled drugm...
published: 01 Mar 2016
Valeant's stock plunges 18 pct as company's headaches mount
Valeant's stock plunges 18 pct as company's headaches mount
- Report rights infringement
- published: 01 Mar 2016
- views: 0
2:17
Valeant Says It's Under Investigation by SEC
Feb. 29 -- Valeant Pharmaceuticals International Inc. is under investigation by the U.S. S...
published: 01 Mar 2016
Valeant Says It's Under Investigation by SEC
Valeant Says It's Under Investigation by SEC
- Report rights infringement
- published: 01 Mar 2016
- views: 136
1:02
Valeant CEO Pearson to Return to Work after Long Illness
Valeant Pharmaceuticals says its CEO, J. Michael Pearson, will be returning to work after ...
published: 29 Feb 2016
Valeant CEO Pearson to Return to Work after Long Illness
Valeant CEO Pearson to Return to Work after Long Illness
- Report rights infringement
- published: 29 Feb 2016
- views: 1
close fullscreen
- Playlist
- Chat
53:06
Как Правильно Покупать Анализировать Акции на Примере Valeant Pharmaceuticals VRX
Применение инструментов Provalue Analytics (PVA) на практике для экспресс анализа компании...
published: 14 Dec 2015
Как Правильно Покупать Анализировать Акции на Примере Valeant Pharmaceuticals VRX
Как Правильно Покупать Анализировать Акции на Примере Valeant Pharmaceuticals VRX
- Report rights infringement
- published: 14 Dec 2015
- views: 93
25:11
REALIST NEWS - Valeant plunges as report alleges Enron-like fraud
http://www.jmbullion.com (Recommended for Silver and Gold Purchases.)
http://www.freespeak...
published: 23 Oct 2015
REALIST NEWS - Valeant plunges as report alleges Enron-like fraud
REALIST NEWS - Valeant plunges as report alleges Enron-like fraud
- Report rights infringement
- published: 23 Oct 2015
- views: 4401
146:22
FNN: House Hearing on Drug Pricing - Martin Shkreli Refuses to Testify
(AP) - Pharmaceutical chief Martin Shkreli has arrived at a hearing where U.S. lawmakers w...
published: 04 Feb 2016
FNN: House Hearing on Drug Pricing - Martin Shkreli Refuses to Testify
FNN: House Hearing on Drug Pricing - Martin Shkreli Refuses to Testify
- Report rights infringement
- published: 04 Feb 2016
- views: 1856
24:59
How To Build Value In The Drug Business
This year's two biggest pharma takeouts were Onyx Pharmaceuticals, purchased by Amgen for ...
published: 18 Oct 2013
How To Build Value In The Drug Business
How To Build Value In The Drug Business
- Report rights infringement
- published: 18 Oct 2013
- views: 710
26:19
"Boom Bust" The Valeant scandal and Steve Keen on China and Portugal
The European Union cuts its Eurozone growth forecast for 2016. Despite this being the thir...
published: 06 Nov 2015
"Boom Bust" The Valeant scandal and Steve Keen on China and Portugal
"Boom Bust" The Valeant scandal and Steve Keen on China and Portugal
- Report rights infringement
- published: 06 Nov 2015
- views: 322
27:26
[142] Bryan Caplan on Parenting and George Selgin with more on Free Banking
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. B...
published: 17 Jun 2014
[142] Bryan Caplan on Parenting and George Selgin with more on Free Banking
[142] Bryan Caplan on Parenting and George Selgin with more on Free Banking
- Report rights infringement
- published: 17 Jun 2014
- views: 2133
52:12
The Evolution of Specialty Pharma and Diagnostics
Moderator, Adele Oliva, Partner at Quaker Partners leads a panel discussion called The Evo...
published: 22 May 2013
The Evolution of Specialty Pharma and Diagnostics
The Evolution of Specialty Pharma and Diagnostics
- Report rights infringement
- published: 22 May 2013
- views: 239
59:48
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10-13-2015
Before the First Cup with Jules - TPP: Sovereignty Lost, DMCA Censorship & Big Pharma 10-8...
published: 13 Oct 2015
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10-13-2015
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10-13-2015
- Report rights infringement
- published: 13 Oct 2015
- views: 37
46:36
Erin
The mudslinging between Allergan and Valeant pharmaceuticals got more intense this week. B...
published: 11 Dec 2015
Erin
Erin
- Report rights infringement
- published: 11 Dec 2015
- views: 7
50:32
Beauty and The Retail Beast: A Snapshot of Online Retailing and the Beauty Industry - SIC2012
Beauty Retail Panel
Shauna Causey, Decide.com (Moderator)
Alissa Hsu Lynch, Valeant Pharm...
published: 28 Feb 2013
Beauty and The Retail Beast: A Snapshot of Online Retailing and the Beauty Industry - SIC2012
Beauty and The Retail Beast: A Snapshot of Online Retailing and the Beauty Industry - SIC2012
- Report rights infringement
- published: 28 Feb 2013
- views: 556
81:21
usa cinque
Beauty Retail Panel Shauna Causey, Decide.com (Moderator) Alissa Hsu Lynch, Valeant Pharma...
published: 03 Dec 2015
usa cinque
usa cinque
- Report rights infringement
- published: 03 Dec 2015
- views: 13
59:48
Before the First Cup with Jules - Guinea Pigs, 21st Century Cures Act, Brain Fingerprints 10-14-15
Before the First Cup with Jules - Big Pharma, Placebo Power, DNA Sterilization Vaccines 10...
published: 14 Oct 2015
Before the First Cup with Jules - Guinea Pigs, 21st Century Cures Act, Brain Fingerprints 10-14-15
Before the First Cup with Jules - Guinea Pigs, 21st Century Cures Act, Brain Fingerprints 10-14-15
- Report rights infringement
- published: 14 Oct 2015
- views: 16
27:16
Boom Bust- Pharma Price Fixing?
Packed Show!
The European Union cuts its Eurozone growth forecast for 2016. Despite this ...
published: 09 Nov 2015
Boom Bust- Pharma Price Fixing?
Boom Bust- Pharma Price Fixing?
- Report rights infringement
- published: 09 Nov 2015
- views: 44
46:57
[135] Free Banking w/George Selgin & Ann Pettifor on Boom-Bust UK Economy
Our lead story: A new report by the Hass Institute at UC Berkley reveals that a one third ...
published: 12 Dec 2015
[135] Free Banking w/George Selgin & Ann Pettifor on Boom-Bust UK Economy
[135] Free Banking w/George Selgin & Ann Pettifor on Boom-Bust UK Economy
- Report rights infringement
- published: 12 Dec 2015
- views: 5
Как Правильно Покупать Анализировать Акции на Прим...
REALIST NEWS - Valeant plunges as report alleges E...
FNN: House Hearing on Drug Pricing - Martin Shkrel...
How To Build Value In The Drug Business...
"Boom Bust" The Valeant scandal and Steve Keen on ...
![[142] Bryan Caplan on Parenting and George Selgin with more](http://web.archive.org./web/20160316031055/http://i.ytimg.com/vi/Gj2K57Z2rbg/0.jpg)
[142] Bryan Caplan on Parenting and George Selgin ...
The Evolution of Specialty Pharma and Diagnostics...
Before the First Cup with Jules - Big Pharma, Plac...
Erin...
Beauty and The Retail Beast: A Snapshot of Online ...
usa cinque...
Before the First Cup with Jules - Guinea Pigs, 21s...
Boom Bust- Pharma Price Fixing?...
![[135] Free Banking w/George Selgin & Ann Pettifor on Boom-Bu](http://web.archive.org./web/20160316031055/http://i.ytimg.com/vi/XzUF6ppUaq4/0.jpg)
[135] Free Banking w/George Selgin & Ann Pettifor ...
CHEX Daily - Monday Oct. 26, 2015...
Oct. 24th, 2015 Stockguy22 Saturday Morning Chart ...
2012 Annual CEO Innovation, Brent Saunders - Bausc...
2006 CEO Innovation Lecture Fred Hassan, Schering-...
Juergen Frevert| Merz Pharmaceuticals GmbH | Germa...
Developments in the Prescription Drug Market: Over...
photo: Sepahnews
Details From January's Iran Capture Of U.S. Sailors Keeps Getting Worse
Edit WorldNews.com 15 Mar 2016
Thousands of pages of information from devices used by U.S. sailors who were briefly detained in January were examined by Iran, an Iranian naval commander said Tuesday, Business Insider reported ... following the incident in the two months that have passed ... – WN.com, Jack Durschlag....
photo: AP / Baba Ahmed, File
'Blasphemous' Christian Books Burned By ISIS In Mosul
Edit WorldNews.com 15 Mar 2016
Pressure is mounting on the U.S. State Department to formally recognize the purge of Christians from Iraq and Syria as genocide, according to a Breitbart report Tuesday ... This is not the first time an ISIS video has made an assault on “blasphemous” writings ... “It was difficult to stay there as a Christian.”....
photo: AP / Wong Maye-E
Why North Korea might not be bluffing about its nuclear plans
Edit The Guardian 15 Mar 2016
Skeptics have dismissed the threat posed by Pyongyang’s weapons programme but the regime has a track record of getting there – eventually. Skeptics of North Korea’s nuclear threat, and there are many, have long clung to two comforting assurances. While the North has the bomb, it doesn’t have a warhead small enough to put on a long-range rocket ... Related. North Korea readying another nuclear bomb for test – Kim Jong-un ... Cause celebre ... ....
photo: AP / Jacques Brinon
Police Counterterrorism Raid Results In Brussels Shootout
Edit WorldNews.com 15 Mar 2016
A counterterrorism raid on a house in southern Brussels Tuesday has injured at least three Belgian police officers, a police spokesman said ... Reporting from Paris, Al Jazeera said “Two suspects have escaped over the rooftops, according to eyewitnesses ... – WN.com, Jack Durschlag....
photo: via Instagram/@lushsux
Kim Kardashian’s Nude Selfie Mural Art Defaced By Slut-Shaming Graffiti
Edit Inquisitr 15 Mar 2016
A huge piece of mural art in Melbourne drew the attention of netizens on Monday, giving new spark to the raging debate over feminism, specifically on how it relates to female empowerment and slut-shaming. The mural art is a depiction of Kim Kardashian’s nude selfie, which broke the internet last week. A new incident concerning the Kardashian mural, however, put an ironic twist to the debate ... @kimkardashian ... The Inquisitr News ....
« back to news headlines
Bill Ackman just released a letter to his investors about Valeant, and it is a ...
Edit Yahoo Daily News 16 Mar 2016
Hedge fund billionaire Bill Ackman just released a letter to investors regarding his position in Valeant Pharmaceuticals, and it is a sight to behold. "We continue to believe that the value of the underlying business franchises that comprise Valeant are worth multiples of the current market price," he wrote ... He even tried to help Valeant acquire Allergan Pharmaceuticals back in 2014 ... Bill AckmanValeant Pharmaceuticals ....
We've never seen Wall Street turn on a stock this violently before
Edit Yahoo Daily News 16 Mar 2016
Wall Street just turned its back on Valeant Pharmaceuticals and its CEO Mike Pearson, and it is unlike anything we've seen before ... Valeant will be penalized if it isn't released by March 16 ... (Valeant) ... Fudged numbers, estimate changes, issues with the company's new business model and partners — the analysts, usually so lenient with Valeant — caught it all. Before Valeant became a pariah, its CEO was considered a genius....
Figuring Out What Valeant Is Really Worth
Edit New York Times 16 Mar 2016
As Valeant Pharmaceuticals’ market value sinks, the company’s future may hinge on what it can get now for the companies it bought ... ....
Valeant, Avon slump; Apple, Mead Johnson rise
Edit The Salt Lake Tribune 16 Mar 2016
New York • Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq stock market. NYSE • Avon Products Inc., down 36 cents to $4.02 The cosmetics company said it will cut 2,500 jobs and move its headquarters to the U.K ... • Valeant Pharmaceuticals International Inc., down $35.53 to $33.51 The drugmaker’s preliminary fourth-quarter profit disappointed investors and it cut estimates for 2016 ... ....
Asian Stocks Drop Before Fed on Commodity Selloff, Stronger Yen
Edit Bloomberg 16 Mar 2016
Asian stocks fell before a Federal Reserve policy decision as a selloff in commodities weighed on material shares and a stronger yen hit Japanese exporters. The MSCI Asia Pacific Index declined 0.4 percent to 126.42 as of 9 a.m. in Tokyo ... China’s National People’s Congress ends Wednesday, while the Fed is expected to keep interest rates unchanged at the conclusion of its two-day meeting ... Valeant Pharmaceuticals International Inc ... ....
Valeant Pharmaceuticals Reports Preliminary Unaudited Fourth Quarter 2015 Financial Information
Edit Stockhouse 15 Mar 2016
Valeant Pharmaceuticals Reports Preliminary ......
Valeant Pharmaceuticals reports fourth-quarter loss of $336.4 million
Edit Canada Dot Com 15 Mar 2016
LAVAL, Que. - LAVAL, Quebec (AP) _ Valeant Pharmaceuticals International Inc. (VRX) on Tuesday reported a fourth-quarter loss of $336.4 million, after reporting a profit in the same period a year earlier ... ....
Stock in Valeant Pharmaceuticals falls to lowest level in three years
Edit Canada Dot Com 15 Mar 2016
MONTREAL - Valeant Pharmaceuticals, once one of Canada's most valuable companies, saw its stock plunge to its lowest level in more than three years on Tuesday after reporting fourth-quarter earnings below expectations and lowering its outlook for 2016 ... ....
Valeant Pharmaceuticals Reports Preliminary Unaudited Fourth Quarter 2015 Financial Information (Valeant Pharmaceuticals International Inc)
Edit Public Technologies 15 Mar 2016
Valeant Pharmaceuticals International Inc) ... LAVAL, Quebec, March 15, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc ... Valeant Pharmaceuticals International, Inc ... (i) Adjusted net income attributable to Valeant Pharmaceuticals International, Inc ... Management uses Adjusted net income attributable to Valeant Pharmaceuticals International, Inc ... Adjusted net income attributable to Valeant Pharmaceuticals International, Inc....
Valeant reports 4Q loss
Edit Austin American Statesman 15 Mar 2016
Valeant Pharmaceuticals International Inc ... The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2.64 per share.FILE - This May 27, 2013, file photo shows signage at Valeant Pharmaceutical's headquarters in Montreal. Valeant reports financial results Tuesday, March 15, 2016 ... Valeant shares have declined 32 percent since the beginning of the year ... Valeant Pharmaceuticals, Earnings Report ....
Valeant plunges on missed results
Edit San Francisco Chronicle 15 Mar 2016
Shares of Valeant Pharmaceuticals crashed Tuesday after the embattled drugmaker failed to reassure investors that it’s getting back on track and even conceded for the first time that it’s technically in danger of defaulting on its debt ... Valeant’s already depressed shares took their biggest one-day tumble ... Valeant Pharmaceuticals International Inc....
Valeant falls short in 4Q, slashes guidance
Edit Austin American Statesman 15 Mar 2016
Embattled Valeant Pharmaceuticals fell short of profit expectations in the fourth quarter and slashed its guidance for the current quarter and year ... Valeant is facing a Securities and Exchange Commission investigation and, separately, scrutiny from Congress over its drug pricing ... Bill Ackman's hedge fund Pershing Square Capital Management is one of Valeant's biggest shareholders ... 31, Valeant Pharmaceuticals International Inc....
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and Eastern European Countries and Turkey (Orexigen Therapeutics Inc)
Edit Public Technologies 15 Mar 2016
(NASDAQ.OREX) today announced Valeant Pharmaceuticals International, Inc ... Valeant Holdings Ireland, is a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc,, which is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics....
- 1
- 2
- 3
- 4
- 5
- Next page »
